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Abstract 
Bacteriocins are ribosomally synthesized antimicrobial peptides (AMPs) and proteins 
produced by bacteria. The two-peptide (class-IIb) bacteriocins consist of two different 
peptides and optimal antimicrobial activity requires the presence of both peptides in 
about equimolar amounts. They exert their antimicrobial activity by rendering the 
target-cell membrane permeable for various small molecules. The two-peptide 
bacteriocin plantaricin EF consists of the two helical peptides PlnE and PlnF and is 
produced by some strains of lactic acid bacteria (LAB). Both PlnE and PlnF contain 
GxxxG motifs which might be involved in helix-helix interactions between the two 
peptides. Both peptides also contain aromatic tryptophan and/or tyrosine residues, 
which are often located in the membrane interface of membrane proteins.  
In this study, variants of the PlnE peptide, which are mutated in its two GxxxG motifs 
(G5xxxG9 and G20xxxG24) and in its tyrosine residue (Y6), were constructed, since such 
constructs might reveal how the PlnE and PlnF peptides interact with each other and 
with target-cell membranes. A total of 27 mutants were constructed by in vitro site-
directed mutagenesis and 11 of the constructed peptide variants, all involving individual 
residue replacements of the two glycine residues in the G5xxxG9 motif, were 
subsequently expressed, purified and assayed in complementation with the wild type 
PlnF peptide. The results revealed that the glycine residue at position 9 (G9) seems to be 
in a sterically restricted environment, since substituting G9 with large hydrophobic and 
large hydrophilic residues resulted in at least a 100 fold reduction in activity. It also 
seems that this glycine residue is in a hydrophobic environment, since replacement with 
a small hydrophobic residue (Ala) was less detrimental (about 10 fold reduction in 
activity) than replacement with a small hydrophilic residue (Ser; 60 to 70 fold reduction 
in activity). In contrast to G9, the glycine residue at position 5 (G5) seems not to be 
restricted by spatial constraints, since substituting with large hydrophobic residues 
(Leu/Ile) resulted in only a 2 to 6 fold reduction in antimicrobial activity. Similarly to 
G9, G5 also appears to be in a hydrophobic environment, since replacement with a large 
hydrophilic residue was detrimental (about 100 fold reduction in activity). The fact that 
G5 was not spatially restricted indicates that the G5xxxG9 motif is not a helix-helix 
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interacting motif. G9, being in a sterically restricted environment, may nevertheless be 
involved in interactions with PlnF and/or a docking protein.  
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1. Introduction 
1.1 Antimicrobial Peptides (AMPs) 
Production of antimicrobial peptides (AMPs) is an ancient and effective defence used 
by a wide variety of organisms to fight pathogens (1). AMPs have been the focus of 
much research during the last decades due to their potential use as therapeutic agents. 
Developing AMPs into new antimicrobial agents is clearly of great interest due to the 
increase in antibiotic-resistant bacteria resulting from large-scale use of antibiotics (2). 
There has also been great interest in developing AMPs into additives for use in animal 
feed and preservation of food, since the use of chemical preservatives has often 
undesirable side-effects (3).  
AMPs are produced by many different kinds of organisms such as mammals (including 
humans), fish, birds, amphibians, insects, plants, fungi and bacteria (4). In animals, 
AMPs are effectors of innate immunity and contribute to a first line of defence during a 
pathogenic invasion, activated within a few hours and long before the adaptive immune 
system is mobilized. Hence, they prevent or delay the onset of infections (1, 5). Each 
species express its own arsenal of AMPs (6), which can consist of up to 35 different 
AMPs from various structural classes (4). Furthermore, experiments with knockout and 
transgenic mice indicate that AMPs often work in concert to combat specific infectious 
agents due to frequently overlapping activity spectra (7). Some AMPs exhibit a very 
selective toxicity, whereas others have a much more broad activity spectrum; the latter 
category includes the mammalian peptides, defensins. Some AMPs may cause harmful 
effects on the producer organism. As a result, many known vertebrate AMPs are 
secreted onto relatively inert epithelial surfaces or retained in granules of phagocytes, 
thereby minimizing negative effects of peptides on the host. In addition, the epithelial 
surfaces are normally more prone to infectious agents, placing the peptides in key 
positions against a potential pathogenic invasion (8).  
As a result of the increased insights regarding the functions of AMPs, the more general 
term (cationic) host defence peptides (HDPs) is about to replace the term AMPs, the 
latter being a more narrow definition when seen in light of their emerging functions in 
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animals. AMPs of bacteria, often referred to as bacteriocins, may also be regarded as 
host defence peptides in that bacteria that produce bacteriocins achieve a competitive 
advantage by killing invading bacteria in their fight for nutrients (2). While eukaryotic 
AMPs are active at micromolar concentrations, bacteriocins are active at nanomolar 
concentrations (2). Generally, the latter also have a more narrow target-cell spectrum 
than AMPs of eukaryotes (2).  
AMPs are gene-encoded, ribosomally synthesized peptides (2). As a result, ‘peptide’ 
antibiotics are not considered to be AMPs because their synthesis is mediated by a 
unique system composed of multifunctional enzymes rather than via ribosomes (2, 9). 
Although antimicrobial peptides make up a diverse group as judged by their primary 
structure, some features seem to be in common; they are often membrane 
permeabilizing, cationic (with a net positive charge ranging from +2 to +9) and 
amphiphilic or hydrophobic when folded (9, 10). These properties are of importance 
when it comes to initial contact with a pathogen since they enable electrostatic and 
hydrophobic interactions between the peptide and the bacterial membrane, which 
consists of negatively charged and hydrophilic head groups as well as a hydrophobic 
core (4, 6).   
1.2 Bacteriocins 
Bacteriocins represent a diverse and abundant group of antimicrobial peptides and 
proteins produced by bacteria. They were first discovered in Escherichia coli (E. coli) 
as substances, named colicins, that inhibited the growth of some strains of E. coli (11). 
After the discovery of colicins, a great number of bacteriocins have been identified in 
many bacteria from different taxonomic branches and habitats (12, 13). Gram-negative 
bacteria often produce protein bacteriocins larger than 20 kDa whereas Gram-positive 
bacteria, including lactic acid bacteria, most often produce peptide bacteriocins smaller 
than 6 kDa (2).  
Lactic acid bacteria (LAB) and their bacteriocins have been the focus of much research 
due to their beneficial influence in fermented foods and the fact that they are generally 
regarded as safe (10, 14). Some LAB are also part of the natural microflora in humans 
  Introduction 
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and are thought to be beneficial to human health, reflecting the increased marketing of 
LAB-containing probiotic products (15). 
The bacteriocin nisin has been formally used as a food preservative for over 30 years 
and is currently the only bacteriocin licensed as a food additive (in a wide variety of 
products) in over 48 countries (16). Pediocin PA-1 has also been commercially 
exploited, particularly in meat products, and as a pediocin-containing powder in dairy 
products (17). Although bacteriocin-producing LAB have been deliberately used in food 
for only a few decades, humans have probably benefited from their influence in 
fermented food for thousands of years (18). LAB bacteriocins have also given 
promising results in medical applications. A recent study showed that oral intake of 
Lactobacillus salivarius UCC118, producing the bacteriocin ABP118, conferred a 
protective effect in mice against the food-borne pathogen Listeria monocytogenes (19). 
Furthermore, a class-IIa bacteriocin (section 1.3), enterocin CRL35, has been shown to 
behave as an antiviral agent against herpes simplex viruses (20).  
1.3 Classification of LAB Bacteriocins 
The LAB bacteriocins can be divided into two main classes, class-I and class-II (Fig 
1.1). Class-I consists of the lantibiotics, which are lanthionine-containing post-
translationally modified bacteriocins. Class-II consists of the non-lanthionine-containing 
bacteriocins (10, 18). The lantibiotics (i.e. class-I bacteriocins) contain the thioether-
linked amino acids lanthionine and 3-methyllanthionine. Up to 15 other modified 
residues (such as dehydroalanine, dehydrobutyrine and D-alanine) have also been 
identified in some lantibiotics (10, 21). Lanthionine and 3-methyllanthionine are formed 
by a two-step mechanism which involves dehydration of serine (to lanthionine) or 
threonine (to 3-methyllanthionine) in the first step followed by a thioether-linkage to a 
sulphydryl group of a cysteine residue in the second step, thus creating the 
intramolecular rings common to all lantibiotics (21). Both one- and two-component 
(two-peptide) lantibiotics have been identified (22). Examples of class-I bacteriocins 
(lantibiotics) are nisin, subtilin and lactocin S (21).  
Introduction   
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Class-II, the non-lanthionine-containing bacteriocins, which are small and heat-stabile, 
may be further subdivided into four subclasses, class-IIa, class-IIb, class-IIc and class-
IId (18). The class-IIa bacteriocins are often referred to as the pediocin-like bacteriocins 
because the first identified bacteriocin in this subclass was pediocin PA-1 (23). These 
peptide bacteriocins are active against pathogenic bacteria such as Staphylococcus 
aureus and Listeria monocytogenes. They contain between 37 to 48 amino acid residues 
and have the consensus sequence YGNGV(X)C(X)4C(X)V(X)4A (where X is any 
amino acid) in the N-terminal region (23). Class-IIc consists of the cyclic bacteriocins in 
which the C- and N-terminal ends are covalently linked. Class-IId contains a 
heterogeneous group of bacteriocins as the class consists of all one-peptide, non-cyclic 
bacteriocins whose sequences have no similarity to the pediocin-like bacteriocins (10, 
18). Class-IIb consists of the two-peptide bacteriocins whose optimal antimicrobial 
activity requires the presence of two different peptides in about equimolar amounts (24). 
The two-peptide bacteriocin plantaricin EF belongs to this subclass and is also the focus 
of this thesis. As such, this subclass will be discussed more thoroughly in the next 
sections.   
 
Fig 1.1 Classification of the LAB bacteriocins. The bacteriocins are divided into two main classes; 
class-I (the lantibiotics) and class-II (the non-lanthionine containing bacteriocins). The latter can be 
further divided into four subclasses. Class-IIa consists of the pediocin-like bacteriocins. The two-peptide 
bacteriocins are categorized in class-IIb. Class-IIc consists of the cyclic bacteriocins, while the non-
cyclic non-pediocin-like bacteriocins are placed in class-IId.   
  Introduction 
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1.4 Class-IIb Bacteriocins 
Both peptides of two-peptide (class-IIb) bacteriocins are usually cationic and contain 
hydrophobic and/or amphiphilic regions (24, 25).  The net positive charge is important 
for their preferential binding to the negatively charged surface of bacteria, such as 
lipopolysaccharides in Gram-negative bacteria and wall-associated teichoic acids in 
Gram-positive bacteria (9). Since their discovery in 1992 (26), more than 15 two-
peptide bacteriocins have been identified and genetically characterized (Table 1.1).  The 
specific antimicrobial activity is generally highest when both peptides are present in 
about equal amounts. Individually, the peptides of two-peptide bacteriocins exert only 
low, if any, antimicrobial activity. For instance, when present together, the two 
complementary peptides (LcnG-α and LcnG-β) of the two-peptide bacteriocin 
lactococcin G are active at less than nanomolar concentrations, but they show no 
activity individually at micromolar concentrations (27).  
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Table 1.1 An overview of characterized class-IIb bacteriocins: 
Bacteriocina) Producer strain References 
Lactococcin G b) Lactococcus lactis LMGT 2081 (26) 
Lactococcin Q b) Lactococcus lactis QU 4 (28) 
Enterocin 1071 b) 
Enterococcus faecalis FAIR-E 309 (29) 
Enterococcus faecalis BFE 1071 (30, 31) 
Enterocin Cc) Enterococcus faecalis C901 (32) 
Enterocin X Enterococcus faecium KU-B5 (33) 
Plantaricin EF d) Lactobacillus plantarum C11 (34, 35) 
Plantaricin JK d) Lactobacillus plantarum C11 (34, 35) 
Plantaricin S Lactobacillus plantarum LPCO10 (36, 37) 
Plantaricin NC8 Lactobacillus plantarum NC8 (38) 
Lactocin 705 Lactobacillus casei CRL 705 (39) 
Lactacin F Lactobacillus johnsonii VPI11088 (40, 41) 
Brochocin C Brochothrix campestris ATCC 43754 (42) 
Thermophilin 13 Streptococcus thermophilus Sfi13 (43) 
ABP-118 Lactobacillus salivarius subsp. salivarius 
 
(44) 
Salivaricin P Lactobacillus salivarius DPC6005 (45) 
Mutacin IV Streptococcus mutans UA140 (46) 
a) Lactococcin MMT24 (47), lactococcin MN (48) and leucocin H (49) are not included in the table. 
Lactococcin MMT24 has not been sequenced whereas lactococcin MN has only been sequenced in the 
preform. Leucocin H has only been partially sequenced.  
b) Lactococcin G, lactococcin Q and enterocin 1071 share high sequence similarities enabling high 
activity when combining one peptide from one of these bacteriocins with the complementary peptide 
from another of these bacteriocins (24). 
c) Enterocin C differs only in one amino acid compared to enterocin 1071, but has a higher inhibitory 
activity as well as a much broader activity spectrum (32).  
d) Plantaricins EF and JK are produced by several different Lactobacillus plantarum strains in addition 
to the strain C11 (25, 50).  
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1.4.1 Expression and Secretion of Two-Peptide Bacteriocins 
For all genetically characterized two-peptide bacteriocins, at least five genes are 
required for bacteriocin production: the two genes encoding the two peptides 
constituting the bacteriocin, a gene encoding the immunity protein that protects the 
bacteriocin-producing bacteria from its own bacteriocin, a gene encoding a dedicated 
ATP-binding cassette (ABC) transporter that exports the bacteriocin out of the cell, and 
a gene encoding an accessory protein whose exact function is unknown, but it may be 
involved in immunity toward and/or secretion of the bacteriocin (27). These genes are 
localized in either the same or in two nearby operons (2, 27). The two genes encoding 
the two peptides constituting the bacteriocin are always located next to each other on the 
same operon along with the gene encoding the immunity protein (24). The genes 
encoding the dedicated ABC transporter and the accessory protein are located either in 
the same operon as the bacteriocin genes (as is the case for lactococcin G (27)) or in a 
nearby operon (as is the case for enterocin 1071 (31) and plantaricins EF and JK (35)) 
(51) .  In addition to the results showing that both bacteriocin peptides need to be 
present to attain a potent antimicrobial effect (24), this organization of genes encoding 
the two bacteriocin peptides in the same transcriptional unit (meaning that the two 
peptides are likely to be produced in about equal amounts) and the fact that there is only 
one immunity protein for a specific two-peptide bacteriocin, strongly suggest that the 
two bacteriocin peptides function as one antimicrobial entity (10, 24). This is in contrast 
to two one-peptide bacteriocins acting synergistically at two different sites on the target 
cell. In fact, a recent study has shown that the two complementary peptides of 
lactococcin G (LcnG-α and LcnG-β) are recognized as one physical entity by their 
cognate immunity protein (52).  
The two peptides of all the two-peptide bacteriocins that have been characterized are 
synthesized with a double-glycine type leader sequence at the N-terminal end, the 
length of the leader being 15 to 30 amino acid residues (24). The N-terminal double 
glycine leader is cleaved off at the C-terminal side of the two glycine residues by the 
ABC transporter concomitantly with export of the peptides. This ABC transporter has 
an N-terminal extension of about 150 amino acid residues which has been shown to 
possess proteolytic activity (51). The N-terminal glycine leader seems to function both 
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as a recognition signal for the ABC transporter and possibly also to keep the bacteriocin 
in an inactive state until it has been secreted (53).  
1.4.2 Regulation of Two-Peptide Bacteriocin Expression 
Some two-peptide bacteriocins (such as lactococcin G (Nissen-Meyer, J., personal 
communication)) seem to be produced constitutively, whereas others (such as ABP-118 
(44) and plantaricins EF and JK (35, 54)), are regulated by a so-called three-component 
regulatory system. The three-component regulatory system consists of a peptide 
pheromone (induction factor), a histidine protein kinase and a response regulator (54-
56). See Fig 1.2 for a schematic overview of regulation of two-peptide bacteriocins. The 
peptide pheromone is produced with an N-terminal leader sequence of the double-
glycine type which is cleaved off upon export across the membrane by the same ABC 
transporter that processes and secretes the bacteriocin. The genes encoding the peptide 
pheromone, the histidine protein kinase and the response regulator are located in the 
same operon (54-56). The expression of the genes is presumably triggered in a cell-
density dependent manner. The peptide pheromone has a low, but constitutive secretion 
during growth. When reaching a threshold concentration, the peptide pheromone 
interacts with the membrane-bound histidine protein kinase that result in 
autophosphorylation of the latter and subsequent phosphorylation of the cytoplasmic 
response regulator. The phosphorylated response regulator binds in turn to DNA and 
activates the operons necessary for transcription of the genes involved in production and 
secretion of the bacteriocin (56, 57). The activation of the histidine protein kinase also 
seems to increase the production of the peptide pheromone itself, thereby creating an 
autoinduction loop ensuring a rapid and massive burst of bacteriocin production (56).   
  Introduction 
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Fig 1.2 A simplified, schematic representation of the regulation of bacteriocin biosynthesis. The 
production of some two-peptide bacteriocins are regulated through a three-component regulatory system 
including a peptide pheromone, a histidine protein kinase and a response regulator. The leader peptides 
of both the peptide pheromone and the bacteriocin are cleaved off concomitant with transport to the 
extracellular medium by a dedicated ABC-transporter. Once outside the cell, the peptide pheromone 
triggers an autophosphorylation of the histidine protein kinase which in turn phosphorylates the 
response regulator. The response regulator then binds to the DNA and activates transcription of the 
genes necessary for production and secretion of the bacteriocin. The bacteriocin and the peptide 
pheromone are not structured in aqueous solutions (58, 59) although this figure represents it that way.   
 
1.4.3 Structure and Mode of Action  
As already mentioned, two-peptide bacteriocins are usually cationic and contain 
hydrophobic and/or amphiphilic regions. Structural studies performed by circular 
dichroism (CD) and nuclear magnetic resonance (NMR) spectroscopy have been carried 
out on three two-peptide bacteriocins, lactococcin G, plantaricin EF and plantaricin JK 
(58, 60-63). The CD studies showed that all the peptides had a non-structured 
conformation in aqueous solutions, but upon exposure to membrane-mimicking 
environments, such as micelles and negatively charged liposomes, they adopted mainly 
an α-helical structure. Furthermore, additional α-helical structuring was obtained in both 
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complementary peptides when they were premixed before they were added to 
liposomes, which might imply that the two peptides interact with each other upon 
contact with target membranes (58, 60). Additional structuring was not observed when 
the two peptides were added to liposomes one after the other (58, 60).  It was also 
shown for lactococcin G that no activity is obtained when cells are first treated with one 
of the two lactococcin G peptides and then mixed with cells treated with the other 
lactococcin G peptide (64). Antimicrobial activity is, however, obtained when cells are 
treated with one of the peptides and then extensively washed before adding the 
complementary peptide (64). These results may suggest that the individual peptides first 
bind to the target-cell surface and then interact with the complementary peptide before 
being fully embedded in the membrane (64). It also seems that once a peptide is bound 
to the target membrane it is unable to diffuse to another membrane (10, 64).  
NMR studies have revealed the 3D structures of the peptides that constitute lactococcin 
G (62), plantaricin EF (61) and plantaricin JK (63). All 6 peptides formed mainly 
amphiphilic α-helices with more flexible regions in the N- and C-terminal halves when 
exposed to membrane-mimicking environments. Although the amphiphilic α-helix 
seems to be an important structural motif in class-IIb bacteriocins, it appears that some 
bacteriocins in this subclass may adopt a β-sheet structure as may be the case for 
brochocin C (24). 3D structural studies when both complementary peptides are present 
have not yet been performed.  
After insertion into the membrane, all two-peptides whose mode of action has been 
studied (this includes plantaricins EF and JK (65), lactococcin G (64, 66), lactacin F 
(67), lactocin 705 (68) and thermophilin 13 (43)) render the membranes of target cells 
permeable to small molecules, eventually leading to cell death. The specificity as to 
what ions they conduct across the membrane of target cells varies among the 
bacteriocins. For instance, lactacin F permeabilizes membranes for K+ and inorganic 
phosphate (67), lactococcin G permeabilizes the membrane for different monovalent 
cations such as K+, Na+, Cs+ and Rb+ (64), but does not conduct H+ as lactococcin G has 
no effect on the transmembrane pH gradient (ΔpH) (64, 66). Plantaricin EF seems to 
conduct monovalent cations more effectively than plantaricin JK (such as Rb+ and 
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choline as well as H+), whereas plantaricin JK seems to conduct anions more effectively 
than plantaricin EF (65).  
 The high potency of two-peptide bacteriocins (antimicrobial activity is observed at 
picomolar to nanomolar concentrations (63, 69)) and their ability to differentiate 
between various molecules they conduct across the membrane, suggest that these 
bacteriocins create specific pores rather than an unspecific disruption of membranes 
(24). Questions about possible interactions between bacteriocins and receptors in the 
target-cell membrane have been raised. The lantibiotic, nisin, has been shown to 
specifically interact with lipid II, a central component in bacterial cell wall synthesis, 
upon binding to the bacterial membrane (70). Moreover, a recent study showed that 
lactococcin A, a class-IId bacteriocin, and pediocin-like bacteriocins (class-IIa) bind to 
part of the mannose phosphotransferase system (man-PTS), a system which is important 
for the uptake of mannose in bacteria (71). The study also showed that the cognate 
immunity protein to lactococcin A binds to the bacteriocin-receptor complex in 
lactococcin A-producing bacteria and thereby prevents the bacteria from being killed by 
lactococcin A. No such interaction was detected between bacteriocins, the man-PTS and 
the cognate immunity proteins of the two-peptide bacteriocins plantaricin EF and 
lactococcin G (71). 
A recent study on lactococcin G and its cognate immunity protein (52) revealed that the 
lactococcin G immunity protein confers resistance toward the highly similar bacteriocin 
enterocin 1071 in an Enterococcus strain, but not in a Lactococcus strain to the same 
extent, indicating that also the lactococcin G immunity protein depends on a cellular 
component (possibly the bacteriocin receptor) in order to function (52). It has indeed 
been suggested that lactococcin G (as well as other two-peptide bacteriocins) function in 
an analogous manner as lactococcin A and the pediocin-like bacteriocins; i.e. by binding 
of lactococcin G to an integrated membrane protein whereby the lactococcin G 
immunity protein recognizes and binds to the bacteriocin-receptor complex, making the 
lactococcin G-producing bacteria immune toward its own bacteriocin (72).   
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1.5 The Two-Peptide Bacteriocin Plantaricin EF 
Various bacteriocin-producing Lactobacillus plantarum (L. plantarum) strains have 
been isolated from vegetable and fermented sources as well as from human mucosa, and 
some of these strains produce the bacteriocin plantaricin EF (25). Plantaricin EF 
consists of the two peptides plantaricin E (PlnE) and plantaricin F (PlnF) and was 
identified by DNA and protein similarity searches in 1996 along with another two-
peptide bacteriocin, plantaricin JK, both produced by L. plantarum C11 (35). The fact 
that they possessed antimicrobial activity was verified two years later in activity assays 
(34). Although the PlnF peptide showed some activity when tested individually (at a 
concentration of 5 µM) their activity is increased at least 103 times when combined and 
optimal activity requires both PlnE and PlnF peptides in about equal amounts. The PlnE 
peptide did not exert any antimicrobial activity at concentrations up to 13 µM when 
tested without the PlnF peptide (34, 58). Both plantaricin EF and plantaricin JK 
bacteriocins display quite narrow inhibition spectra and are mainly active against 
closely related species of L. plantarum (25).  
1.5.1 Induction of Plantaricin EF Expression 
The production of the two-peptide bacteriocins plantaricins EF and JK and their cognate 
immunity proteins is controlled by a three-component regulatory system as described in 
section 1.4.2. The pln loci responsible for bacteriocin production and regulation in L. 
plantarum C11 are organized into five inducible operons (Fig 1.3) where the inducer is 
the peptide pheromone plantaricin A (PlnA) (73). PlnA was previously thought to be a 
bacteriocin because of its antimicrobial activity and the fact that it contained a double-
glycine type leader sequence (74-76), but was later found to possess both bactericidal 
and pheromone activities with its main biological function being its pheromone activity 
(59). The results showed that the all-D-enantiomer of a truncated version of PlnA 
remained bactericidal in vivo, but the pheromone activity was lost, indicating that its 
pheromone activity involves chiral interactions with a receptor protein (presumably the 
histidine protein kinase), whereas its antimicrobial activity involves a non-chiral 
interaction with membrane lipids (77).    
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1.5.2 Regulation and Expression of Plantaricin EF 
As illustrated in Fig 1.3, five operons are important for regulation and expression of 
plantaricins EF and JK and the transcription of these operons are all induced by the 
peptide pheromone PlnA. Two of the five PlnA-induced operons, plnEFI and plnJKLR, 
encode the two two-peptide bacteriocins plantaricin EF (and its cognate immunity 
protein PlnI) and plantaricin JK (and its cognate immunity protein PlnL), respectively 
(35). The putative protein encoded by the plnR-gene has a yet unknown function, but it 
might be required for the protein PlnL to confer immunity against plantaricin JK (78). 
The two genes plnGH that are located in the transport operon, plnGHSTUVW, encode 
an ABC transporter (PlnG) and an accessory protein (PlnH) involved in the maturation 
and export of peptides containing double-glycine type leader sequences (25, 35). What 
role in bacteriocin biosynthesis the remaining genes in this operon (plnSTUVW) may 
have is still unknown, but they show significant sequence similarity to each other as 
well as to plnI, plnL and plnP (the latter from the operon with unknown function) and to 
the Abi protein family, a family of proteins with putative proteolytic activity (25, 78). 
The regulatory operon, plnABCD, codes for the peptide pheromone PlnA, a histidine 
protein kinase (PlnB) and two response regulators, PlnC and PlnD. The fact that this 
operon contains two response regulators is in contrast to what is observed with many 
other known three-component regulatory systems, including those of other L. plantarum 
strains where only one response regulator has been identified (25, 79). The functions of 
the regulators PlnC and PlnD are complex and their action is still not fully understood, 
but they seem to play a part in the regulation of bacteriocin biosynthesis by an interplay 
between transcriptional activation (mediated by PlnC) and repression (mediated by 
PlnD) of the genes involved in bacteriocin production and regulation. Both regulators 
bind to conserved tandem repeats located in the promoters of all five operons (80). The 
functions of the genes located in the final PlnA-induced operon, plnMNOP, remain to 
be determined. The PlnN peptide was originally thought to be a bacteriocin because the 
plnN-gene encoded a double-glycine type leader sequence and the mature peptide had a 
putative amphiphilic α-helix, but synthetic PlnN exhibited no bactericidal activity when 
assayed against different indicator strains (34).   
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Fig 1.3 Genetic map of the pln locus containing 5 PlnA-induced operons required for production 
and regulation of the two-peptide bacteriocins plantaricin EF and plantaricin JK. The entire pln 
locus is approximately 18 kb long (NCBI accession X94434.2) and is organized into 5 inducible 
operons consisting of a total of 22 ORFs (25). The operons plnEFI and plnJKLR encode the two-peptide 
bacteriocins plantaricin EF and plantaricin JK as well as their cognate immunity proteins PlnI and PlnL, 
respectively. PlnABCD encodes the peptide pheromone PlnA, the histidine protein kinase PlnB and two 
response regulators, PlnC and PlnD, whereas the genes encoding the ABC transporter (PlnG) and the 
accessory protein (PlnH) are located in the operon plnGHSTUVW. The rest of this operon along with the 
plnMNOP-operon encode putative proteins with unknown functions as is also the case for the genes 
orfZ1 (black arrow) and plnQ (pink arrow) (25). Lollipops indicate regulated promoters. The figure is 
adapted from Diep et al.  (25).  
 
The two peptides of the plantaricin EF bacteriocin (as well as plantaricin JK) are 
synthesized as prepeptides containing the typical class-II AMP double-glycine type 
leader sequence in their N-terminal end (Fig 1.4). Concomitant with transport, this 
leader sequence is cleaved off at the C-terminal end of two glycine residues by the 
gene-product of plnG  encoding an ABC transporter (35). The length of the amino acid 
sequences of the leader peptides of PlnE and PlnF are 23 and 18 residues long, 
respectively. The mature peptide of PlnE contains 33 amino acid residues with a 
theoretical molecular weight of 3545 and an isoelectric point (pI) of 11.57. The mature 
peptide of PlnF contains 34 amino acid residues with a molecular weight of 3703 and a 
pI of 10.27 (molecular weights and pIs have been computed based on their mature 
amino acid sequences from the web-site: http://www.expasy.org/tools/, ‘Compute 
pI/Mw’; august 2010) . The sequences are adapted from EMBL Nucleotide Sequence 
Database, accession number X94434.2. 
 
Fig 1.4 Amino acid sequences of the preforms of PlnE and PlnF from N- to C-terminal end. The 
two glycine residues of the double-glycine type leader sequence are marked in green and the cleavage 
site (cleaved by the ABC transporter) is marked with a black triangle. The C-terminal side of this 
triangle indicates the mature peptide. The glycine residues in the three GxxxG motifs (two in PlnE and 
one in PlnF) are marked in red.   
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1.5.3 Structure and Mode of Action of Plantaricin EF 
When in contact with the target-cell membrane, the plantaricin EF bacteriocin induces 
pore-formation, causing an efflux of monovalent cations such as choline, Rb+ and H+, 
which eventually leads to dissipation of the transmembrane electric potential (Δψ) and 
subsequent cell death (65). Plantaricin EF also dissipates the ΔpH, but to a much lesser 
extent than dissipation of the Δψ. It should be mentioned that the plantaricin JK 
bacteriocin dissipates the ΔpH much more effectively than the Δψ (the opposite of what 
is observed with plantaricin EF) by membrane leakage of anions (65). It also seems that 
plantaricin JK more effectively inhibits growth of susceptible cells than does plantaricin 
EF. This might imply that ΔpH is more important for cell viability, leading to a drop in 
the intracellular pH and thereby inhibition of metabolism and depletion of the cellular 
ATP pool, resulting in a more rapid cell death (65).  
As mentioned in section 1.4.3, CD analyses of PlnE and PlnF peptides showed that both 
adopt an amphiphilic α-helix upon contact with membrane-mimicking environments 
such as dodecylphosphocholine (DPC) micelles and negatively charged 
dioleoylphosphoglycerol (DOPG) liposomes, but that they are unstructured in aqueous 
solutions (58). Additional structuring was induced by interpeptide interactions, but only 
when they were premixed and then exposed to negatively charged liposomes. No 
interpeptide-induced structuring was seen when they were simultaneously exposed to 
trifluoroethanol or DPC micelles, the latter possibly due to the fact that micelles are 
much smaller than liposomes and therefore also possess a steeper curvature (61). The 
above results indicate that (i) preferential binding to target membranes is due to 
electrostatic interactions between the cationic peptide and the negatively charged 
membrane surface and that (ii) PlnE and PlnF induce additional structuring in each 
other upon contact with the target membrane. The 3D structures of the individual PlnE 
and PlnF peptides have been determined by NMR spectroscopy in the presence of DPC 
micelles (61). Figs 1.5 A and 1.5 B show the structures of both PlnE and PlnF, 
respectively, along with Edmundson α-helical wheel presentations of parts of their α-
helical region (58). Earlier CD analyses and Edmundson wheel predictions of 
amphiphilic helices within the two peptides of PlnE and PlnF were found to include 
residues 1 to 24 and 15 to 34, respectively (58). This prediction turned out to be in good 
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agreement with the results obtained by NMR spectroscopy. PlnE was shown to form 
two separate amphiphilic α-helices, one α-helix spanning from residue 10 to 21 and the 
other from residue 25 to 31, while PlnF forms one long α-helix from residue 7 to 34 
with a proline residue in the middle resulting in a kink of 38 ± 7 degrees at the position 
of the proline. The helix in PlnF was hydrophobic in the C-terminal part whereas the N-
terminal part (between residue 11 and 16) was very polar and because of this, the 
peptide is not likely to transverse a membrane without interacting with other molecules, 
indicating a possible interaction with an unknown membrane protein (61). 
 
 Fig 1.5 A) The NMR structures of the individual plantaricin EF peptides and B) Edmundson α-
helical wheel presentations of parts of their α-helical region. A) The NMR structure of PlnE and 
PlnF was determined in the presence of DPC micelles. The PlnE peptide forms two α-helices from 
residue 10 to 21 and from 25 to 31. The PlnF peptide forms one long α-helix spanning from residue 7 to 
34. The three asterisks indicate the GxxxG motifs and they are located in the flexible regions of the two 
peptides (see below, section 1.5.4). The figure is adapted from Fimland et al. (61). B) The Edmundson 
α-helical wheel presentations of the peptides PlnE and PlnF show that both peptides can adopt an 
amphiphilic α-helical structure. The polar residues are coloured in black whereas the non-polar residues 
are coloured in white. Glycine residues are treated as being neutral with respect to polarity and are 
therefore coloured in both black and white depending on the position in the wheel. The figure is adapted 
from Hauge et al. (58).  
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1.5.4 The GxxxG Motif 
One or more GxxxG motifs (where x is any amino acid) have been identified in all two-
peptide bacteriocins discovered so far (27). The presence of GxxxG or ‘GxxxG-like’ 
(such as AxxxA and SxxxS) motifs has emerged as a characteristic signature of helix-
helix interactions in many transmembrane proteins (81). When these motifs are 
positioned in an α-helical segment, the small glycine residues are on the same side of 
the helix and thus form an almost flat contact surface, enabling close interhelical 
contact. This will allow for interpeptide van der Waals interactions as well as formation 
of stabilizing interhelical backbone Cα—H∙∙∙O hydrogen bonds (82, 83). The GxxxG 
motifs are thought to be important for the interhelical interactions between two-peptide 
bacteriocins (27), although the motifs by themselves are probably not sufficient for 
creation of the helix-helix interactions (84). Based on site-directed mutagenesis studies 
and NMR analysis, a structural model of the two-peptide bacteriocin lactococcin G 
(which consists of the two peptides LcnG-α and LcnG-β) when integrated in target-cell 
membranes has been proposed (Fig 1.6) (10, 62, 72). Site-directed mutagenesis analysis 
indicates that two of the three putative helix-helix interacting GxxxG motifs in 
lactococcin G are important in helix-helix interactions (72). Replacement of the glycine 
residues in these motifs with larger residues (both hydrophobic and hydrophilic) 
reduced the antimicrobial activity dramatically, whereas replacement with small amino 
acids such as alanine (hydrophobic) and serine (hydrophilic) were reasonably well 
tolerated (72).  
 
Introduction   
18 
 
 
Fig 1.6 The proposed structural model of lactococcin G and its orientation in target-cell 
membranes (an example of how the two peptides of two-peptide bacteriocins may interact with 
each other and the target membrane). The two peptides seem to interact through the G7xxxG11 motif 
in LcnG-α and the G18xxxG22 motif in LcnG-β, forming a parallel transmembrane helix-helix structure. 
Further stabilization of the structure and orientation/anchoring in the membrane may be favoured by the 
positively charged C-terminal end of LcnG-α and the tryptophan-rich N-terminal end of LcnG-β, 
positioned at each side of the membrane interface, as well as the C-terminal Trp residue (W32) in LcnG-
β (72). The figure is adapted from Nissen-Meyer et al. (27).  
 
The PlnE peptide contains two putative helix-helix interacting GxxxG motifs, one 
positioned from residue 5 to 9 (G5xxxG9) and one from residue 20 to 24 (G20xxxG24), 
whereas the PlnF peptide contains one such motif from residue 30 to 34 (G30xxxG34). 
All three GxxxG motifs are marked with an asterisk in Fig 1.5 A. Based on the results 
from NMR spectroscopy, these regions are flexible, but will become more rigid upon 
helix-helix interactions between the two peptides. This may possibly explain the 
increased structuring which has been observed by CD analysis when PlnE and PlnF are 
mixed before exposure to liposomes (58, 61). Two plausible interaction models, 
describing a parallel and an anti-parallel orientation of the two peptides, have been 
proposed (85). The first possibility is that the two peptides interact in a parallel fashion 
leading to a pairing between the G20xxxG24 motif in PlnE and the G30xxxG34 motif in 
PlnF, which in turn will enable charge-charge interactions between different amino acid 
residues in both peptides (85). This will also allow the G5xxxG9 motif in PlnE to come 
in close contact with the flat surface of PlnF at the region between residues 16 and 20 
where the proline residue (P20) is positioned (Fig 1.5 A). There are also two small 
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amino acid residues located in this area of PlnF, serine (S16) and glycine (G19) (85). A 
second possibility is that the two peptides interact in an anti-parallel manner upon 
interaction between the G5xxxG9 motif in PlnE and the flat surface of PlnF, which also 
will enable interpeptide charge-charge interactions (85). See Fig 5.1, section 5.2 for an 
illustration of the two putative helix-helix interacting models.  
1.5.5 Tryptophan and Tyrosine Residues 
Compared to the hydrophobic core of the membrane, the membrane interface comprises 
a complex environment offering a number of different possibilities of non-covalent 
interactions to which the residue side chains of membrane proteins and peptides can 
interact (86). The aromatic residues tryptophan and tyrosine are known to be 
preferentially located in the membrane interface of membrane proteins, suggesting an 
important role in promoting binding and folding of these (86-89). Indeed, results from 
site-directed mutagenesis studies regarding lactococcin G (72) (see Fig 1.6 for a cartoon 
model of lactococcin G embedded in a target-cell membrane) showed that substituting 
the tryptophan residue at position 32 in the LcnG-β peptide with both large hydrophobic 
and large hydrophilic residues were relatively detrimental, whereas substituting with an 
aromatic residue (such as tyrosine and phenylalanine) was almost as good as wild type 
activity (72). This preference for aromatic residues, but not for hydrophobic residues, 
indicate that this tryptophan residue is positioned in the membrane interface (72).  
The mature PlnE peptide contains one tyrosine residue at position 6 (Y6; Fig 1.4) and 
the mature PlnF peptide contains two tyrosine residues (Y5 and Y14) and one 
tryptophan residue (W23). The role these residues may play in correct positioning of 
plantaricin EF in target-cell membranes remains to be elucidated.  
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2. Aim of Study 
An overall aim of structure-function characterization of the two-peptide bacteriocin 
plantaricin EF is to determine how the two bacteriocin peptides, PlnE and PlnF, interact 
with each other and how they interact with target membranes.  
Most, if not all, two-peptide bacteriocins discovered so far contain a putative 
amphiphilic or hydrophobic α-helix as well as one or more GxxxG motifs. Such motifs 
are known to mediate helix-helix interactions in membrane proteins and one might 
postulate that these motifs are important for the alleged interhelical packing between the 
two peptides of two-peptide bacteriocins upon interaction with target-cell membranes. 
Tryptophan and tyrosine residues are often found in membrane proteins and are 
preferentially located in the membrane interface. Mutational studies of the GxxxG 
motifs and aromatic tyrosine and tryptophan residues in two-peptide bacteriocins may 
thus provide insight into the structure of two-peptide bacteriocins and the orientation of 
the structure in target-cell membranes. The PlnE peptide contains two GxxxG motifs 
(G5xxxG9 and G20xxxG24) and one tyrosine (Y6) residue, but no tryptophan residues.  
The aim of this study was to construct variants of the PlnE peptide that are mutated in 
the two GxxxG motifs and in the tyrosine residue, since such constructs might reveal 
how the PlnE and PlnF peptides interact with each other and with target-cell 
membranes. The glycine residues in both GxxxG motifs in PlnE were thus to be 
individually replaced with a small hydrophobic (alanine) residue or a small hydrophilic 
(serine) residue or with large hydrophobic (leucine/isoleucine) residues or large 
hydrophilic (lysine/glutamine) residues. The tyrosine residue was to be replaced with a 
hydrophobic (leucine) residue, a hydrophilic (arginine) residue or aromatic 
(tryptophan/phenylalanine) residues.  
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3. Methods 
3.1 Bacteria Related Methods 
3.1.1 Preparation of Competent E. coli DH5α  
E. coli DH5α cells were inoculated in 3 ml Luria-Bertani (LB) medium with vigorous 
agitation (250 rpm) at 37 °C over night (ON). A 0.5 ml ON culture was used to 
inoculate 25 ml fresh LB medium. The cells were grown with vigorous agitation at      
37 °C until the optical density at 600 nm (OD600) reached a value of approximately 0.3. 
The culture was then chilled on ice for 10 min to prevent further growth before the 
culture was centrifuged at 5000 rpm for 10 min at 4 °C. The supernatant was discarded 
and the cells were resuspended in 5 ml ice cold 0.1 M CaCl2 and incubated on ice for 5 
min. Exposing the cells to calcium ions make them more susceptible for uptake of 
foreign DNA (90). Again, the mixture was centrifuged at 5000 rpm for 10 min at 4 °C. 
The supernatant was discarded and the cells resuspended in 1 ml 0.1 M CaCl2 
containing 15% (v/v) glycerol. The cell suspension was left on ice for approximately 45 
min and 100 µl aliquots of competent cells were stored at -80 °C.  
3.1.2 Transformation of E. coli DH5α 
The plasmids (pGEM®-T Easy Vector with insert or the pPlnE100 plasmids) were 
transformed into E. coli DH5α cells according to the QuikChange® site-directed 
mutagenesis protocol (91). The competent E. coli DH5α cells were gently thawed on ice 
and 1 µl of the plasmid DNA (approximately 50 ng/µl) was added to a volume of 50 µl 
competent cells and immediately transferred on ice for 30 min. The transformation 
reaction was heat pulsed for 90 seconds (sec) in a microcentrifuge tube at 42 °C for 
efficient uptake of DNA. The transformation reaction was then incubated on ice for 2 
min. A 0.5 ml of LB medium preheated to 42 °C was added to the cell suspension and 
incubated at 37 °C with vigorous agitation (250 rpm) for up to 1 hour before the 
suspension was plated on LB agar plates containing the appropriate antibiotic and 
incubated ON at 37 °C. Depending on the plasmid, the LB agar plates were added either 
erythromycin (Sigma) to a final concentration of 150 µg/ml (for selection of pPlnE100) 
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or ampicillin (Calbiochem) to a final concentration of 100 µg/ml (for selection of the 
pGEM®-T Easy Vector).  
3.1.3 Preparation of Competent Lactobacillus sakei Lb790/pSAK20 
The following procedure was performed as described by Aukrust et al. (92). A 25 ml 
ON culture of Lactobacillus sakei (L. sakei) Lb790/pSAK20 cells were inoculated in 
100 ml de Man-Rogosa-Sharpe (MRS) medium supplemented with glycine to a final 
concentration of 2% (w/v) and incubated at 30 °C until reaching an OD600 of 
approximately 0.6. Chloramphenicol (Sigma) was added to the growth media (to a final 
concentration of 10 µg/ml) to ensure that the pSAK20 plasmid was retained in the cells. 
The supernatant was discarded after the cells were centrifuged for 7 min at 5000 rpm,   
4 °C. The cells were resuspended in ice cold 1 mM MgCl2 and again centrifuged for 7 
min at 5000 rpm, 4 °C. After another resuspension, this time in 30% ice cold 
polyethylene glycol (PEG), the cells were centrifuged for 10 min at 7000 rpm, 4 °C, and 
100 µl aliquots of competent cells were stored at -80 °C.  
3.1.4 Transformation of L. sakei Lb790/pSAK20 
A volume of 2 µl plasmid DNA (approximately 50 ng/µl) was added to 50 µl competent 
L. sakei Lb790/pSAK20 cells on ice immediately before electroporation. The 
transformation reaction was carefully transferred to an ice cold electroporation cuvet (2 
mm electrode gap) and the electric pulse (making transient holes in the membrane for 
uptake of DNA) was delivered with the following values:  
Voltage: 1.5 kV 
Capacitance: 25 µF 
Resistance: 400 Ω 
 
The resulting time constants varied between 9.0-9.5.  
Immediately after the discharge, 1 ml MRS medium supplemented with 0.5 M sucrose 
and 0.1 M MgCl2 (MRSSM medium) was added to the electroporation cuvet, gently 
swirled and transferred to a microcentrifuge tube. The transformation reaction was 
incubated at 30 °C for 2 h. A volume of 200 µl of the suspension was applied to MRS 
  Methods 
25 
 
agar plates containing 2 µg/ml erythromycin and 5 µg/ml chloramphenicol (Sigma) for 
selection of pPlnE100 and pSAK20, respectively. The agar plates were incubated at    
30 °C for up to 3 days (92).  
3.1.5 Strains, Cultivation and Storage 
Genomic DNA from L. plantarum C11 was used as a template in two of the four PCR-
reactions performed when creating the insert for construction of the pPlnE100 plasmid 
(see section 3.5.1 for construction of pPlnE100). The cells were grown in MRS medium 
at 30 ºC ON without agitation. For long term storage, 850 µl of ON culture was added 
150 µl glycerol to a final concentration of 15% and stored at -80 ºC. Glycerol was added 
to decrease the freezing temperature, thus preventing the cells from lysing. 
E. coli DH5α cells were used for amplification and subsequent isolation of the 
pPlnE100 plasmids and the pGEM®-T Easy Vector (Promega) containing the final PCR 
product. After transformation, the cells were plated out on LB agar plates containing 
either a final concentration of 150 µg/ml erythromycin for selection of pPlnE100 
plasmids or a final concentration of 100 µg/ml ampicillin for selection of pGEM®-T 
Easy Vectors with insert. A single colony was added to 3 ml LB containing the 
appropriate antibiotic and incubated ON with vigorous agitation (250 rpm) at 37 ºC. For 
long term storage, a 15% glycerol stock was stored at -80 ºC.   
L. sakei Lb790/pSAK20/pPlnE100 cells were used for production of wild type and 
mutant peptides of PlnE. The cells were grown in MRS medium at 30 ºC without 
agitation. Both chloramphenicol and erythromycin were added to a final concentration 
of 10 µg/ml for selection of pSAK20 and pPlnE100, respectively.  
The indicator strains used in the bacteriocin activity assays were grown in MRS 
medium or GM17 medium (depending on the strains used) at 30 ºC ON without 
agitation. For long term storage, the culture was added glycerol as above.  
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3.2 DNA Related Methods 
3.2.1 DNA Isolation from L. plantarum C11 
The QIAGEN DNeasy® Tissue Kit was used to isolate genomic DNA from L. 
plantarum C11.  The isolation was performed according to the protocol for purification 
of genomic DNA from Gram-positive bacteria (provided by the manufacturer). A total 
volume of 5 ml ON culture was used to harvest cells.   
3.2.2 Plasmid Isolation from E. coli DH5α 
A Macherey-Nagel NucleoSpin® Plasmid Kit was used to isolate plasmid DNA from E. 
coli according to the protocol specified by the manufacturer. A total volume of 3 ml ON 
culture was used for purification of plasmids and the elution-step was carried out with 
50 µl distilled H2O (dH2O).  
3.2.3 DNA Purification from Agarose Gel or Solution 
The illustra™ GFX™ PCR DNA and Gel Band Purification Kit (GE Healthcare) was 
used to purify DNA either from an enzymatic reaction or from an agarose gel. 
Purification was carried out according to the protocol except for the elution step where 
the isolated DNA was eluted in 30 µl dH2O instead of the elution buffer supplied by the 
manufacturer.   
3.2.4 Restriction Digests of DNA 
The restriction enzymes used were ClaI (Promega) and MluI (Promega). They both 
recognize and cleave a 6 basepair long palindromic sequence while creating sticky ends 
on each strand of a dsDNA. For unidirectional cloning, two different restriction 
enzymes creating sticky ends should be used to ensure correct ligation of insert. After 
digestion, the two DNA fragments to be ligated together will have overlapping sticky 
ends. In a subsequent DNA ligation reaction, one end of the insert DNA cleaved by the 
first restriction enzyme will basepair with the overlapping end of the target DNA 
sequence while the other end of the insert DNA cleaved by the second restriction 
  Methods 
27 
 
enzyme will basepair with the corresponding overlapping end of the target DNA 
sequence. An illustration of the DNA fragments applied in this thesis after restriction 
digestion by ClaI and MluI is shown in Fig 3.1.  
 
 
 
Fig 3.1 Restriction digestion of the insert DNA and vector DNA by ClaI and MluI. Nucleotides 
marked in blue indicate the sticky ends created by MluI and the nucleotides marked in red indicate the 
sticky ends created by ClaI. The black lines (dense and stapled) define the vector DNA and the green 
lines define the insert DNA.  
 
 
A double restriction digestion with ClaI and MluI was performed with the pGEM®-T 
Easy Vector with insert and the pLT100β plasmid (a pLPV111 derivative). Buffer C 
gives a 50-75% of MluI enzyme activity and a 100% ClaI enzyme activity. The 
restriction digest reactions were carried out according to the protocol provided by the 
manufacturer (Promega): 
 
5 µl RE 10X Buffer C 
0.5 µl of 10 µg/µl acetylated bovine serum albumine (BSA) 
0.5-3 µg substrate DNA 
1.3 µl ClaI (10 U/µl) 
1.3 µl MluI (10 U/µl) 
dH2O to a final volume of 50 µl 
 
The amount of DNA was measured with the Thermo Scientific NanoDrop ND-1000 
Spectrophotometer. The reaction mixture was incubated at 37 °C for 2 hours. After 
complete digestion, the reaction mixture was applied to a 1% agarose gel (section 3.4) 
for isolation and purification for downstream ligation reaction (section 3.2.6).  
3.2.5 DpnI-Treatment of Plasmid DNA 
The enzyme DpnI is an endonuclease specific for m6N methylated adenine in both 
methylated and hemimethylated DNA with the target sequence 5’-Gm6ATC-3’ (91). 
The parental plasmid DNA isolated from E. coli DH5α cells contains this target 
sequence and is therefore susceptible to digestion by DpnI. The mutated plasmid DNA 
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created by PCR does not contain this methylation and will therefore remain intact after 
treatment.  
Treatment of plasmid DNA with DpnI (Fermentas) was used to digest the parental 
pPlnE100 plasmid after performing site-directed mutations according to the 
QuikChange® site-directed mutagenesis protocol (91). A volume of 1 µl (10 U/µl) DpnI 
was added to a 50 µl PCR solution and left for 1 hour at 37 ºC.   
3.2.6 DNA Ligation 
Ligation of insert into a vector (after digestion with the same restriction enzymes) was 
performed using a DNA ligase. In this thesis, two ligation reactions were performed. 
The first reaction involved sub-cloning of the PCR product (the insert) into the pGEM®-
T Easy Vector (section 3.3.5) and the second ligation reaction involved ligation of the 
insert into the pLPV111 plasmid (the pLT100β plasmid becomes a linear pLPV111 
plasmid after restriction digestion). Both ligation reactions were performed according to 
the protocol provided by Promega and Fermentas, respectively:  
 
Ligation of insert into the pGEM®-T Easy Vector: 
5 µl 2X Rapid Ligation Buffer (Promega) 
1 µl of 50 ng/µl pGEM®-T Easy Vector 
1-3 µl PCR product (amount depending on the insert:vector molar ratio used, see below) 
1 µl of 3 U/µl T4 DNA Ligase (Promega) 
dH2O to a final volume of 20 µl 
 
 
Ligation of insert into the pLPV111 plasmid:  
2 µl 10X Ligation buffer (Fermentas) 
1-9 µl vector DNA (50-400 ng) 
1-9 µl insert DNA (amount depending on the insert:vector molar ratio used, see below) 
0.5 µl of 10 mM ATP (Amersham Biosciences) 
0.5 µl of 5 U/µl T4 DNA Ligase (Fermentas) 
dH2O to a final volume of 20 µl 
 
The insert:vector molar ratios used were 1:1, 3:1 and 5:1. A positive control was 
performed in the pGEM®-T Easy Vector ligation reactions with the addition of 2 µl (4 
ng/µl) Control Insert DNA. For ligation in both pGEM®-T Easy Vector and the 
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pLPV111 plasmid, a negative control was performed without the insert DNA to check 
for self-ligation of the plasmid. The ligation reactions were incubated at 4 °C ON.  
3.2.7 DNA Sequencing 
A sequencing sample was prepared and delivered to our sequence facility which uses 
the BigDye® Terminator v3.1 Cycle Sequencing Kit and an ABI PRISM® 3730 DNA 
Analyzer for DNA sequencing.   
 
The sequencing sample: 
4-8 µl DNA (150-300 ng of plasmid DNA or 10-40 ng of PCR product) 
0.5 µl of a 20 µM sequencing primer 
dH2O to a final volume of 10 µl 
 
An overview of all sequencing primers used in this study is listed in the Appendix, 
section 6.4.1.  
3.3 Polymerase Chain Reaction (PCR) 
Polymerase Chain Reaction (PCR) is a simple method for amplifying specific DNA 
fragments on a defined DNA sequence. It is often used to introduce additional 
sequences such as restriction sites or the introduction of site-directed mutations in the 
original DNA sequence (93). For each cycle of amplification performed, the amount of 
target DNA currently present is doubled (94). A PCR reaction typically consists of 16-
30 cycles. When exceeding this number, the amount of newly synthesized product is 
limited by the amount of primers present (94). The main components in the reaction-
mixture are: a thermo stabile DNA polymerase, two oligodeoxynucleotide (oligo) 
primers (forward and reverse), a DNA template, the four deoxynucleoside triphosphates 
(dNTPs; dATP, dTTP, dGTP and dCTP) and an optimal buffer for the DNA 
polymerase. Each cycle includes three steps: denaturation, annealing and 3’ extension. 
In the first step, the dsDNA is heat denatured into single stranded DNA (ssDNA). In the 
second step, the temperature is lowered to make sure the primers anneal to their 
complementary region in the target DNA sequence. The thermo stabile DNA 
polymerase then synthesizes the complementary DNA strand in the third and last step 
by adding dNTPs to the 3’ end of both primers (forward and reverse) and thereby 
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completing the synthesis of the desired DNA sequence. When the thermo-cycling is 
done, an extra 3’ extension-step is performed to ensure complete elongation of the final 
PCR product.  
Three different DNA polymerases have been used in this study: Pfu DNA polymerase 
(Fermentas), PfuTurbo DNA polymerase (Stratagene) and Taq DNA polymerase 
(Fermentas). Taq DNA polymerase was used when it was necessary to make dATP-
overhangs in each 3’-end of the PCR product to facilitate ligation into a pGEM®-T Easy 
Vector System. All the PCR reactions applied in this thesis were carried out using a MJ 
Research PTC-200 Peltier Thermal Cycler. The different primers used for creation of 
insert and site-directed mutagenesis were ordered from Eurogentec S.A. and are listed in 
the Appendix, section 6.4.  
3.3.1 Gradient PCR 
Gradient PCR is a useful way to test for optimal annealing temperatures for primers. 
This can help minimize the effect of unspecific primer-annealing by increasing the 
specificity, thus creating fewer non-specific extension-products leading to increased 
quantity of the targeted DNA fragment (94).The temperatures were set to span between 
48 ºC and 59 ºC and the value which gave the strongest DNA-band after gel 
electrophoresis was set as default in the subsequent PCR programs.  
3.3.2 The PCR Megaprimer Method 
The megaprimer method can be used for site-directed mutagenesis (95) as well as 
making a fusion-product out of two different DNA-sequences. In general, this method 
utilizes three oligonucleotide primers and two rounds of multiple cycles of PCR to 
create the desired PCR product. In the first reaction, two oligonucleotide primers anneal 
to their complementary DNA fragment for amplification. One of the primers contains a 
tail complementary to the DNA to be amplified in the second PCR. The resulting PCR 
product from the first PCR reaction can then be used as a megaprimer in the second 
round of PCR. Together with a third oligonucleotide primer, a completely new DNA 
sequence may be synthesized. An important distinction between the PCR megaprimer 
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method and the regular PCR method is that the megaprimer, in addition to partial 
overlap of the second template DNA, also has a tail at one end comprising the first 
PCR-product. The megaprimer thereby unites two different DNA sequences, making a 
longer DNA sequence than both the precursors.  
Parameters for the Megaprimer Method 
The megaprimer method was used to make a fusion-product of the sakacin A promoter, 
the sakacin P leader sequence and the plnE-gene encoding the mature PlnE peptide as 
well as coupling the beginning of the plnI-gene (encoding the cognate immunity 
protein) to this sequence. In the first round of PCR, the template DNA was the pLT100β 
plasmid (Appendix, section 6.6), created for another two-peptide bacteriocin construct. 
The two primers SakPB and PlnEA (both from Eurogentec S.A.) were used to amplify 
the gene encoding the sakacin P leader sequence as well as the sakacin A promoter and 
a restriction site for MluI positioned upstream of the promoter region. The PlnEA 
primer contains a tail complementary to the beginning of the plnE-gene. The resulting 
PCR product can be used as a megaprimer in the second round of PCR; hence it was 
termed Megaprimer 1 (Fig 3.2, round 1). In the next round of PCR, the template DNA 
was genomic DNA from L. plantarum C11, which contains the plnEFI-operon. 
Megaprimer 1 and the PlnEC primer (Eurogentec S.A.) were used to amplify the plnE-
gene. In addition, the PlnEC primer contains a tail containing the beginning of the plnI-
gene. The product of the second round of PCR, named Megaprimer 2, will now consist 
of the sakacin A promoter, the plnE-gene fused to the gene encoding the sakacin P 
leader sequence and the beginning of the plnI-gene (Fig 3.2, round 2).  
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Fig 3.2 The megaprimer method illustrating the first two rounds of PCR. Round 1: The sakacin P 
leader sequence, the sakacin A promoter region and the restriction site for MluI from the pLT100β 
plasmid are fused together with the beginning of the plnE-gene by the primers SakPB and PlnEA, 
creating Megaprimer 1 for the second round of PCR. The grey box to the right in Megaprimer 1 and 
Megaprimer 2 indicates the sakacin A promoter region with a restriction site for MluI. Round 2:
 
 
Megaprimer 1 and the primer PlnEC anneals to each end of the plnE-gene from the genomic DNA of L. 
plantarum C11, having a tail comprising the sakacin P leader sequence and the beginning of the plnI-
gene, respectively. The product now consists of the sakacin A promoter, the sakacin P leader sequence, 
the plnE-gene and the beginning of the plnI-gene as well as the restriction site for MluI, denoted 
Megaprimer 2 as for the next PCR reaction.   
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The reaction conditions for the first and second PCR reactions were carried out 
according to the protocol provided by the manufacturer (Fermentas):  
 
Round 1:  
5 µl Pfu Buffer (without MgSO4) 
6 µl of 25 mM MgSO4 
8 µl of 5 mM dNTP mix (1.25 mM each; Pharmacia Biotech) 
1-4 µl pLT100β plasmid DNA (50 – 100 ng) 
5 µl of 20 µM SakPB  
5 µl of 20 µM PlnEA  
0.5 µl of 2.5 U/µl Pfu DNA polymerase  
dH2O to a final volume of 50 µl  
 
Round 2: 
5 µl Pfu Buffer (without MgSO4) 
6 µl of 25 mM MgSO4 
8 µl of 5 mM dNTP mix (1.25 mM each) 
2 µl genomic DNA of L. plantarum C11 (0.1 – 1 µg) 
5 µl of 20 µM PlnEC  
5-10 µl Megaprimer 1 (230 ng) 
0.5 µl of 2.5 U/µl Pfu DNA polymerase  
dH2O to a final volume of 50 µl 
 
After an initial heat shock for degradation of interfering enzymes, Pfu DNA polymerase 
was added to the mixture. The cycling parameters are listed in Tables 2.1 and 2.2.  
Table 2.1 Cycling parameters for the PCR megaprimer method, round 1: 
Step Temperature Time Cycle 
Heat shock 95 ºC 2 min 1 
Denaturing 
 
 
 
 
              
95 ºC 1 min 25 
Annealing 48 ºC 1 min  
Extension 72 ºC 2 min (2 min/kb) 
Extension 72 ºC 7 min 1 
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Table 2.2 Cycling parameters for the PCR megaprimer method, round 2: 
Step Temperature Time Cycle 
Heat shock 95 ºC 10 min 1 
Denaturing 
 
 
 
 
              
95 ºC 45 sek 25 
Annealing 55 ºC 1 min  
Extension 72 ºC 2 min (2 min/kb) 
Extension 72 ºC 7 min 1 
 
3.3.3 PCR Splicing by Overlap Extension (PCR SOEing) 
PCR SOEing is a simple way of fusing two DNA fragments together, creating 
mutations and/or deletions as well the generation of recombinant DNA products (93). 
Generally, it involves two independent PCR reactions and one third, “splicing” reaction. 
The first two sample reactions contain both one external and one internal primer. The 
internal primer contains the mutation of interest. The internal primers are 
complementary to each other, thereby enabling the two products to overlap. Both the 
external and internal primers anneal at each 3’ end of the target DNA sequence. The 
third PCR reaction involves splicing by elongation of the two overlapping PCR 
products. In the first cycles of this last round of PCR, the two PCR products are added 
to the reaction mixture. As they overlap at each 3’ end, they will act as primers for each 
other; hence the DNA polymerase will extend the hybridized fragments from each 3’ 
end, making the final PCR product. When the PCR product is synthesized, two external 
oligo primers are added to the reaction mixture, each complementary to the 3’ end of the 
two PCR products from the first two rounds of PCR, thereby letting the DNA 
polymerase amplifying the final product (93).  
Parameters for PCR SOEing 
The PCR SOEing method was used to fuse the plnI-gene together with the resulting 
fragment (termed Megaprimer 2) from the megaprimer method by overlap extension, 
thereby creating the final PCR product (the insert). The template DNA in the first round 
of the PCR SOEing method was genomic DNA of L. plantarum C11. The two primers 
added were PlnEFimmstart and PlnEFimm (both from Eurogentec S.A.). 
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PlnEFimmstart contains a tail complementary to the plnE-gene and PlnEFimm contains 
a point mutation making a restriction site for ClaI, positioned downstream of the plnI-
gene for later insertion into an expression vector. The DNA polymerase then amplifies 
the plnI-gene (Fig 3.3). This intermediary PCR product and Megaprimer 2 were spliced 
together in the next step (Fig 3.4). The spliced PCR product was amplified by adding 
the two external primers, primer PlnEFimm and SakPB (Fig 3.4). The final PCR 
product now consists of the entire plnI-gene, the plnE-gene fused to the gene encoding 
the leader sequence of sakacin P and the sakacin A promoter region. The restriction site 
for ClaI is positioned after the plnI-gene, and the restriction site for MluI is positioned 
in front of the promoter region of sakacin A.  
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Fig 3.3 The PCR SOEing method illustrating the first PCR SOEing reaction. Primer PlnEFimm 
contains a point mutation making a restriction site for ClaI at the downstream region of the plnI-gene 
when extended. PlnEFimmstart anneals to the beginning of the plnI-gene while at the same time 
carrying a tale comprising the end of the plnE-gene, making an intermediary product which will overlap 
with Megaprimer 2 in the final PCR reaction (Fig 3.4).  
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Fig 3.4 The PCR SOEing method illustrating the second PCR SOEing reaction. The intermediary 
product overlaps with Megaprimer 2, acting as primers for each other when the DNA polymerase 
extends the two sequences from each 3’ end. For amplification of the final PCR product, the two 
primers PlnEFimm and SakPB are added in the last cycles of the final PCR reaction. The grey box to the 
right in Megaprimer 2 and the final PCR product indicates the sakacin A promoter region with a 
restriction site for MluI. 
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The reaction conditions were carried out according to the manufacturer (Fermentas): 
1. PCR reaction of PCR SOEing:  
5 µl Pfu Buffer (without MgSO4) 
6 µl of 25 mM MgSO4  
8 µl of 5 mM dNTP mix (1.25 mM each) 
2 µl genomic DNA of L. plantarum C11 (0.1 – 1 µg) 
2.5 µl of 20 µM PlnEFimm 
2.5 µl of 20 µM PlnEFimmstart  
0.5 µl of 2.5 U/µl Pfu DNA polymerase  
dH2O to a final volume of 50 µl 
 
2. PCR reaction of PCR SOEing: 
5 µl Pfu Buffer (without MgSO4) 
6 µl of 25 mM MgSO4  
8 µl of 5 mM dNTP mix (1.25 mM each) 
210 ng intermediary PCR product 
210 ng Megaprimer 2 
5 µl of 20 µM SakPB  
2.5 µl of 20 µM PlnEFimm 
0.5 µl of 2.5 U/µl Pfu DNA polymerase  
dH2O to a final volume of 50 µl 
 
After an initial heat shock for degradation of interfering enzymes, Pfu DNA polymerase 
was added to the mixture in both PCR reactions. After 10 cycles of PCR in the second 
PCR reaction the primers SakPB and PlnEFimm were added for amplification of the 
final PCR product. Cycling parameters for both reactions are listed in Table 2.3.  
Table 2.3 Cycling parameters for the PCR SOEing method: 
Step Temperature Time Cycle 
Heat shock 95 ºC 10 min 1 
Denaturing 
 
 
 
 
              
95 ºC 45 sek 25 a)/10b)/25c)  
Annealing 48 ºC 1 min  
Extension 72 ºC 3 min (2 min/kb) 
Extension 72 ºC 7 min 1 
a) The first PCR reaction (creating the intermediary product) was performed with 25 cycles. 
b) The first step of the second PCR reaction (for splicing of the two DNA fragments) was performed with 
10 cycles. 
c) The final step of the second PCR reaction (for amplification of the final PCR product)  was performed 
with 25 cycles.  
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3.3.4 QuikChange® Site-Directed Mutagenesis 
QuikChange® site-directed mutagenesis is a technique which can be used for the 
creation of point mutations, switching of amino acids and deletion/insertion of single or 
multiple amino acids. It is a rapid four-step procedure (Fig 3.5) that generates specific 
mutated plasmids with greater than 80% efficiency (91).  
The protocol includes the use of a double stranded plasmid DNA, two mutagenic oligo 
primers and the PfuTurbo DNA polymerase (Stratagene). The primers are 
complementary to each other and the plasmid DNA to be amplified. After initial 
denaturation of the plasmid DNA and subsequent annealing of primers, PfuTurbo DNA 
polymerase elongates the mutated plasmid DNA, leaving the PCR product with 
staggered nicks. The product is then treated with the endonuclease DpnI (section 3.2.5) 
which digests the parental plasmid DNA, leaving only the nicked plasmids containing 
the desired mutation. The fourth and last step of this procedure is to transform the 
nicked plasmids into competent E. coli DH5α cells, which will then repair the nicks 
(91).  
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Fig 3.5 The four-step procedure for QuikChange® site-directed mutagenesis. Step 1: A plasmid 
DNA containing the gene with the target site is constructed. Step 2: The plasmid is denatured by 
thermal cycling and the two synthetic oligonucleotide primers containing the desired mutation anneal to 
each strand of the template DNA at the site of mutation. The PfuTurbo DNA polymerase extends and 
incorporates the mutagenic primers, creating nicked DNA plasmids. Step 3: The nonmutated, 
methylated parental strand is digested by treatment with DpnI. Step 4: The nicked, mutated plasmid is 
repaired when transformed into competent E. coli DH5α cells. The figure is adapted from QuikChange® 
site-directed mutagenesis protocol (91). 
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Parameters for Quik Change Site-Directed Mutagenesis 
In this thesis, the method was used to introduce a specific point mutation leading to 
single amino acid changes in the plnE-gene. Each mutation was constructed by the use 
of specific primers, a forward (F) primer and a reverse (R) primer annealing each strand 
of the plasmid DNA (pPlnE100) at the desired site of mutation. The site-directed 
mutations were performed basically according to the instruction manual from the 
QuikChange® site-directed mutagenesis kit (91). All the primer sequences used for the 
introduction of the desired mutations into the plnE-gene are listed in the Appendix, 
section 6.4.2. The primers were ordered from Eurogentec S.A. The reaction conditions 
were carried out according to the QuikChange® mutagenesis protocol (Stratagene): 
The PCR mixture:  
5 µl 10X Cloned Pfu Reaction Buffer 
1 µl plasmid DNA (5 – 50 ng)  
1.3 µl forward primer (130 ng) 
1.3 µl reverse primer (130 ng) 
2 µl of 5 mM dNTP-mix (1.25 mM each) 
1 µl of 2.5 U/µl PfuTurbo DNA polymerase     
38.4 µl dH2O to a final volume of 50 µl 
 
After an initial heat shock, PfuTurbo DNA polymerase was added to the mixture.  
3.3.5 The pGEM®-T Easy Vector System 
The pGEM®-T Easy Vector System can be used for cloning of a PCR product. The 
vector is prepared by cutting with the restriction enzyme EcoRV and subsequent 
addition of 3’ terminal thymidine to both ends. The PCR product to be inserted is 
likewise treated with a thermostable DNA Polymerase which adds a 3’ terminal 
deoxyadenosine in a template-independent fashion in both ends. This prevents 
recirculization of the vector in a subsequent ligation reaction as well as providing an 
overlapping overhang between the PCR product and the vector. The vector also contains 
a multiple cloning site (MCS) as well as a gene encoding the enzyme β-galactosidase 
positioned within this region. This allows for blue-white screening of recombinant 
clones (96). A circle map of the pGEM®-T Easy Vector is listed in the Appendix, 
section 6.6.  
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Parameters for the pGEM®-T Easy Vector Cloning 
The pGEM®-T Easy Vector System was put to use for sub-cloning of the PCR product 
(the insert). Addition of a 3’ terminal deoxyadenosine to both ends of the insert was 
performed with the Taq DNA Polymerase (Fermentas) in a thermal cycler:  
 
Addition of a single 3’ terminal deoxyadenosine overhang:  
1 µl 10X Taq Buffer with (NH4)2SO4  
1 µl of 25 mM MgCl2  
1 µl of 2 mM dATP (Pharmacia Biotech) 
6 µl PCR product  
1 µl of 5 U/µl Taq DNA Polymerase 
10 µl total  
 
The reaction was incubated at 70 ºC for 30 min. See section 3.2.3 for purification of the 
enzymatic reaction.  
3.4 Agarose Gel Electrophoresis 
Agarose gel electrophoresis is a method used to separate DNA and RNA molecules by 
size. Agarose is a polysaccharide which will form a porous matrix upon heating when 
added to an electrophoresis buffer. An electrical field is applied to the gel and the 
negatively charged DNA will be sieved through the pores towards the anode. The 
velocity of the DNA molecule is proportional to its size, thus the shorter the lengths of a 
DNA fragment, the greater is its elecrophoretic mobility (97). For plasmids, the 
migration rate is as follows: Supercoiled plasmid > circular plasmid > linearized 
plasmid. Different factors affecting the migration rate of the DNA molecule have to be 
taken into consideration when performing agarose gel electrophoresis: the concentration 
of the agarose, the voltage applied and the composition and ionic strength of the buffer. 
A high concentration of agarose yields smaller pores; hence DNA will spend more time 
wandering toward the anode than in larger pores. At high electrical field strengths, the 
mobility of the DNA molecule will increase, but this may as well decrease the 
resolution of the separation. At low ionic strength of the buffer, the DNA will migrate 
slowly because of the low electrical conductivity (97). When preparing the gel, the 
solution is heated up to its boiling point in order to dissolve the agarose. After cooling, 
ethidium bromide (EtBr) is added to the liquid gel-solution. EtBr is an intercalating 
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agent which enters the space between the bases in the DNA double helix and functions 
as a fluorescent dye. The DNA can then be visualized under ultraviolet (UV) light 
which can reveal distinct band patterns.  
The plasmid DNA, the restricted DNA fragments and the PCR products were analyzed, 
and where appropriate, excised from the agarose gel. A 1% (w/v) agarose solution was 
made by dissolving 0.5 g agarose (Merck) in 50 ml Tris-acetate-EDTA (TAE) buffer by 
heating in a microwave oven. After cooling to 60 °C (to make sure no degradation of 
EtBr will occur), EtBr was added before casting the gel. The agarose gel electrophoresis 
was usually run for 45 min at 70 volts (V) and with an electrical current of 80 milli 
ampere (mA). The DNA ladders used for sizing were the 100 bp DNA Ladder, 100 bp 
DNA Ladder Plus or the 1 kb DNA Ladder (all manufactured by Fermentas). The DNA 
ladders are shown in the Appendix, section 6.5. 
3.5 Protein Related Methods 
3.5.1 Expression of Wild Type and Peptide Variants of PlnE 
A heterologous expression system of class-II bacteriocins in a bacteriocin-deficient host 
strain, producing bacteriocins at levels equal to or higher than the corresponding wild 
type strain has been described (98). This may help determine the effect of different 
bacteriocins in food, to construct new LAB strains with improved protective properties 
and to improve the efficiency of expression systems for structure-function analysis by in 
vitro site-directed mutagenesis (98). The system is based on the introduction of two 
plasmids into the bacteriocin-deficient strain L. sakei Lb790 and the expression of a 
class-IIa bacteriocin, sakacin A. The genes necessary for production of sakacin A are 
located on two divergently transcribed operons and have been shown to complement 
each other when separated on two plasmids (99). One operon contains the gene 
encoding sakacin A, sapA, and its cognate immunity protein, encoded by the gene saiA. 
The other operon, orf4-sapKRTE, encodes the three-component regulatory unit 
responsible for the control of bacteriocin production and synthesis of proteins involved 
in bacteriocin secretion. The genes encoding the regulatory unit encompasses orf4  
(encodes a peptide pheromone (100)), sapK (encodes a histidine protein kinase) and 
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sapR (encodes a response regulator) (99). The genes encoding the proteins involved in 
secretion are sapT (encodes an ABC transporter) and sapE (encodes an accessory 
factor) (99). The orf4-sapKRTE-operon is located on the pSAK20 plasmid along with a 
marker for chloramphenicol-resistance (cat) (99). The second plasmid, a pLPV111 
derivative, contains the structural and immunity genes of the bacteriocin of interest 
fused to the sakacin A promoter as well as a marker for erythromycin-resistance (ermL) 
(98). The plasmid pLPV111 and its derivatives are shuttle-vectors that can be replicated 
in both E. coli and L. sakei. All plasmids used in this study are shown in the Appendix, 
section 6.6.  
The heterologous expression system was used for the production of wild type and 
peptide variants of PlnE. The cognate immunity protein, PlnI, was co-expressed for 
protection of the producer strain. Also, a previous study has implicated that a slight 
increase in bacteriocin-production is seen when the immunity-gene is expressed 
together with the bacteriocin (101).   
A pLPV111 derivative, named pPlnE100, containing the structural (plnE) and immunity 
gene (plnI) of PlnE fused to the sakacin P leader sequence and the sakacin A promoter 
was constructed. The operon plnEI is now placed under control of the sakacin A 
promoter. Previous studies have demonstrated that the sakacin A secretion machinery 
encoded in pSAK20 recognizes both the sakacin A and sakacin P leader peptides 
equally efficient (98). The plasmid pPlnE100 was constructed from another pLPV111 
derivative, named pLT100β. The latter plasmid carries the sakacin A promoter, the gene 
encoding LcnG-β (one of the peptides constituting the two-peptide bacteriocin 
lactococcin G) fused to the sakacin P leader sequence, as well as the gene encoding the 
lactococcin G immunity protein. It also contains a marker for erythromycin-resistance 
(ermL). The pPlnE100 plasmid was constructed by digesting the insert as well as the 
pLT100β plasmid with the restriction enzymes ClaI and MluI (section 3.2.4), creating a 
linearized pLPV111 plasmid. After digestion, the insert was ligated into the vector.  
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3.5.2 Chromatographic Separation of Proteins 
Chromatography is a common method for purification of proteins and for analysis of 
proteins in a sample. The principle of the separation of a protein in chromatography is 
roughly based upon a system of two phases, in biochemistry normally being either 
liquid-liquid or liquid-solid (102). The stationary phase is attached to the column while 
the mobile phase (termed eluent when applied to the column and eluate when eluting 
from the column along with the components) is a free flow of liquid passing through the 
stationary phase. In a liquid-liquid system, the proteins may or may not partition 
themselves between the two phases depending on their solubility. In a liquid-solid 
system, the proteins can adsorb at varying degrees to the solid phase. In either scenario, 
the concentration ratio of a protein can be expressed as the partition coefficient, K 
(eq. 2.1)    
             
where CS and CM are the sample concentrations in the stationary and mobile phases, 
respectively (102). Two disparate proteins will have different partition coefficients, thus 
being retained on the column at varying degrees and therefore also migrate through the 
column at different velocities (different retention times).  
A rapid two-step procedure for purification of pediocin-like bacteriocins and other 
cationic antimicrobial peptides has been described by Uteng et al. (103). The method is 
based on the cationic and hydrophobic properties of antimicrobial peptides. The first 
purification step relies on the passage of bacterial cultures through a cation-exchange 
column and subsequent elution with 1 M NaCl, whereas the second purification step 
removes remaining contaminants by the use of reverse-phase chromatography upon 
elution with propanol. Isolation and purification of wild type and peptide variants of 
PlnE was performed basically according to the procedure described by Uteng et al. 
(103), but with the addition of 2-propanol (at a final concentration of 20% (v/v)) to the 
elution buffer in cation-exchange chromatography in order to obtain a higher yield of 
peptides in this step (Oppegård, C., personal communication).  
M
S
C
CK =
Methods   
46 
 
3.5.3 Cation-Exchange Chromatography 
In biochemistry, ion-exchange chromatography is a method for separating water-soluble 
proteins (as well as DNA) in a solution by taking advantage of their different surface 
charges at a given pH. Knowledge about a proteins surface charge and its isoelectric 
point (pI) can be used to separate it from other components in a sample. Ion-exchange 
chromatography is a liquid-solid system, thus the proteins will adsorb to the stationary 
phase based on the attraction between the net charge of the protein and the charged 
groups attached to the stationary phase. The solid support (the stationary phase) is made 
up of polymers such as cellulose and agarose. The ion exchangers are covalently bonded 
to the solid support and are either negatively or positively charged. An anion-exchanger 
has covalently bound cations and exchangeable anions, whereas a cation-exchanger has 
covalently bound anions and exchangeable cations (102). In cation-exchange 
chromatography, a protein with a net positive charge will adsorb to the negatively 
charged functional groups, while a protein with net negative charge or no net charge 
will pass through the column in conjunction with the mobile phase. When eluting the 
proteins, the column is conditioned with a large excess of salt, thus exchanging the 
adsorbed protein with a counterion. Alternatively, the pH of the mobile phase can be 
altered in the direction to which the protein changes its net charge to the opposite, 
resulting in a very weak or non-existent attraction between the functional groups and the 
protein.  
Parameters for Cation-Exchange Chromatography 
The peptides PlnE and PlnF are both positively charged at neutral pH and are therefore 
good candidates for separation by cation-exchange chromatography. A cation-
exchanger SP-Sepharose Fastflow column from GE Healthcare was used for the first 
purification step. The material consisted of 6% crosslinked agarose with sulphopropyl 
(SP) groups covalently bound to it and the column had a volume of 100 ml. A 10 ml ON 
culture was applied to 1 liter (L) of MRS medium containing erythromycin and 
chlormaphenicol to a final concentration of 10 µg/ml for selection of the plasmids 
pPlnE100 and pSAK20, respectively. The cells were grown to stationary phase and 
were then directly applied to the cation-exchange column after equilibration with a 20 
mM phosphate buffer (pH 6). After 1 L of cell culture had been poured through the 
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column (approximately 10 column volumes), the column was washed with 1 column 
volume of the phosphate buffer. The peptides were eluted with 40 ml of a 1 M NaCl, 20 
mM phosphate buffer containing 20% (v/v) 2-propanol (pH 5.5). The eluate was sterile-
filtrated through a 0.20 µm non-pyrogenic sterile filter (Sarstedt).  
3.5.4 Reverse-Phase Chromatography 
In reverse-phase chromatography, proteins and peptides are separated by their 
differences in net hydrophobicity. The separation is based on a liquid-liquid partition 
system where the support is made up of microporous particles of silica and the 
stationary phase is covalently attached to the polymer (104). In biochemistry, the 
stationary phase generally consists of a non-polar hydrocarbon chain and the mobile 
phase is more polar than the stationary phase. The proteins will partition themselves 
between the stationary and mobile phases based on hydrophobic interactions to the 
former (102). When performing gradient elution, the eluent strength will increase as the 
mobile phase becomes less polar. The peptides with low net hydrophobicity are the ones 
with the shortest retention times and the peptides with the highest net hydrophobicity 
will have the longest retention times, hence elute closer to the end of the gradient step.  
In this study, reverse-phase chromatography using the ÄKTA system (Amersham 
Biosciences) was used as the second purification step for removing remaining 
contaminants in the peptide solution. 
Parameters for Reverse-Phase Chromatography 
All of the eluate (40 ml) obtained from the cation-exchange column was diluted by a 
factor of four with dH2O/0.1% (v/v) trifluoroacetic acid (TFA) and applied to the 
reverse-phase column (3 ml RESOURCE™ RPC, GE Healthcare) consisting of 
polystyrene/divinylbenzene. The elution step was performed using a linear, segmented 
elution gradient divided into three segments. The first segment started at 0% (v/v) 2-
propanol/0.1% (v/v) TFA and ended at 20% (v/v) 2-propanol/0.1% (v/v) TFA. The 
volume of eluent was set to 3 ml (1 column volume). The second segment started at 
20% (v/v) 2-propanol/0.1% (v/v) TFA and ended at 60% (v/v) 2-propanol/0.1% (v/v) 
TFA and the volume of eluent was set to 30 ml (10 column volumes). The third segment 
started at 60% (v/v) 2-propanol/0.1% TFA and ended at 100% (v/v) 2-propanol/0.1% 
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TFA. Again, the volume of eluent was set to 3 ml (1 column volume). The solution 
containing dH2O/0.1% (v/v) TFA had a pH of approximately 2 and the solution 
containing 2-propanol/0.1% (v/v) TFA had a pH of approximately 4. The flow rate of 
the mobile phase was 2 ml/min, and the absorbance at 280 nm and 214 nm was recorded 
as a function of ml eluent.  
3.5.5 Analyzing the Degree of Purity 
The degree of purity from the fractions containing the wild type and mutant peptides of 
PlnE was analyzed by analytical reverse-phase chromatography using the SMART 
system (Amersham Biosciences). The column used was a µRPC C2/C18 Sc.2.1/10 
(Amersham Biosciences) and the gradient was set to range from 0% (v/v) 2-
propanol/0.1% (v/v) TFA to 50% (v/v) 2-propanol/0.1% (v/v) TFA. The volume of 
eluent was 2 ml. The mobile phase flow rate was 100 µl/min and the absorbance at 214 
nm was recorded as a function of ml eluent.  
3.5.6 Matrix Assisted Laser Desorption Ionisation Time-of-Flight (MALDI-
TOF)  
In general, mass spectrometry (MS) is a method for analysis of components by 
measuring their mass/charge (m/z) ratios by the formation of molecular ions in a 
sample. It consists of an ionisation source, an analyser and a detector. The size of the 
molecules defines the amount of deflection in a magnetic field. A large ion will be 
deflected to a lesser extent than a smaller ion with identical charge (102). Matrix-
assisted laser desorption ionisation (MALDI) is a method for molecular weight 
determination of proteins and peptides in a sample. The sample and a suitable matrix is 
bombarded and vaporised in a jet with pulses of high-energy UV radiation. The matrix 
absorbs most of the energy, enabling the sample components to stay intact during 
radiation. The sample molecules are ionised by the excited matrix molecules, creating 
predominantly positively single-charged sample molecules, but multi-charged 
molecules may also be formed (102). MALDI can be combined with a time-of-flight 
(TOF) analyser where the ions are accelerated down a drift tube without a magnetic 
field (Fig 3.6). The ions will have the same kinetic energy, meaning that the velocity 
(and their TOF) will only depend on their molecular masses. The amount of time each 
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ion spends travelling through the drift tube toward the detector is measured and the m/z 
value is calculated (102).  
 
Fig 3.6 Schematic overview of MALDI-TOF MS. The sample and matrix is bombarded and vaporised 
with a pulse of UV radiation, thereby creating positively charged sample molecules (MH+) by the 
excited matrix molecules. The sample ions are accelerated down the drift tube so that they can be 
separated based on their time-of-flight and their m/z ratios can be calculated.  
 
A volume of 10 µl of each sample was delivered to MS/Proteomics Core Facility at the 
Department of Chemistry and Biotechnology, Norwegian University of Life Sciences, 
Ås.  
3.5.7 Estimation of Peptide Concentrations 
PlnE and most of the peptide variants of PlnE contain only one residue (a tyrosine 
residue) with absorbance at 280 nm and the extinction coefficient of the peptides at 280 
nm is consequently relatively low. The concentration of the purified peptides obtained 
after reverse-phase chromatography was too low to quantitate the amount of peptides by 
measuring the absorbance at this wavelength. As a consequence, the absorption peaks 
obtained at 214 nm upon reverse-phase chromatography were used to quantitate the 
peptides (i.e. by measuring the peak areas and subtracting estimated background noise). 
The extinction coefficient of the peptides at 214 nm was estimated to be approximately 
50000 M-1cm-1, calculated from the contributions of the individual amino acid residues 
at 214 nm and the peptide bonds (105).    
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3.5.8 Bacteriocin Activity Assay 
For detection of antimicrobial activity of the wild type and peptide variants of PlnE, a 
microtiter plate assay system was used, essentially as described by Nissen-Meyer et al. 
(26). The growth of the indicator cells was measured spectrophotometrically at 600 nm 
by use of a MR700 Microplate Reader from Dynatech. Each well of the microtiter plate 
contained M17 medium supplemented with 0.4% (wt/v) glucose and 0.1% (v/v) Tween 
80 (GM17 medium) or MRS medium, the mutated or wild type PlnE peptide, the wild 
type PlnF peptide, and the indicator strain, all to a final volume of 200 µl. The dilution 
factor of the peptide combinations was twofold going from one well to the next. 
Stationary phase cultures of indicator strains were diluted 1:50 or 1:200 before added to 
the microtiter plate wells. Incubation temperature was set to 30 ºC and the microtiter 
plates were incubated for 5-6 hours for indicator strains diluted 1:50 and ON for 
indicator strains diluted 1:200. The indicator strains used when assaying the mutant 
PlnE peptides were Lactobacillus viridescens NCDO 1655 and Lactobacillus curvatus 
89 LMGT 2355, both grown in the presence of MRS medium. 
The minimum inhibitory concentration value (MIC value) was defined as the amount of 
wild type or peptide variants of PlnE that inhibited the growth of the indicator strain by 
50%, under the above mentioned conditions. In other words, the wild type PlnE peptide 
(or the mutant PlnE peptide) is the one which is being quantitated in terms of MIC 
values. The concentration of wild type PlnF was applied to the wells in a molar excess 
compared to the concentration of wild type or mutant PlnE peptides.  
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4. Results 
4.1 Construction of the pPlnE100 Plasmid 
The expression plasmid, pPlnE100, was constructed for production and expression of 
wild type and peptide variants of PlnE without its complementary peptide, PlnF, for 
easier isolation and purification from a culture medium. The sakacin P leader sequence 
was fused to the plnE-gene to complement the pSAK20 plasmid necessary for 
transcriptional regulation and secretion of the bacteriocin (98). The plnI-gene encoding 
the plantaricin EF immunity protein was also included in the pPlnE100 plasmid 
downstream of the plnE-gene to ensure protection of the producer strain. Both the plnE-
gene fused to the sakacin P leader sequence and the plnI-gene were placed under control 
of the sakacin A promoter. Plasmid charts of pPlnE100 and pSAK20 are shown in the 
Appendix, section 6.6.  
4.1.1 Synthesis of Insert by PCR 
The megaprimer method (section 3.3.2) was used to fuse the sakacin A promoter and 
sakacin P leader sequence to the plnE-gene (Megaprimer 1, 334 bp; Fig 4.1 A), 
resulting in a product of 434 bp, termed Megaprimer 2 (Fig 4.1 B). The next step was to 
amplify the plnI-gene from the genomic DNA of L. plantarum C11 and at the same time 
introduce a restriction site for the restriction enzyme ClaI downstream of the plnI-gene 
(Fig 4.1 C). The size of the product was expected to be 970 bp long. This product was 
then spliced together with Megaprimer 2 by PCR SOEing (section 3.3.3) and amplified 
in the final PCR reaction (Fig 4.1 D), creating the final PCR product with a length of 
1374 bp. All the PCR products were purified using a GFX kit (section 3.2.3) after gel 
electrophoresis (section 3.4). The correct sequences were verified by DNA sequencing. 
The sequencing primers are listed in the Appendix, section 6.4.1.    
 
 
 
Results   
52 
 
 
 
  
 
 
 
Fig 4.1 Verification of the four PCR products by agarose gel electrophoresis. A) The PCR product 
of Megaprimer 1. B) The PCR product of Megaprimer 2. C) An intermediary PCR product which 
overlaps with Megaprimer 2. D) The final PCR product (the insert).  
A) Megaprimer 1 B) Megaprimer 2 
C) Intermediary product D) Final PCR product 
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4.1.2 Ligation of Insert into Vectors 
It has been shown that ligation reactions involving the pLPV111 plasmid together with 
an insert containing the same sequence as in this thesis with the exception of 
exchanging the plnE-gene with its complementary two-peptide bacteriocin gene, plnF, 
is unsuccessful in that the plasmid will re-ligate rather than integrate the insert (106). 
Both the plasmid and insert were cut with the same restriction enzymes (MluI and ClaI) 
as was done in this study. According to the study, the linearized plasmid was then 
dephosphorylated in order to inhibit re-ligation, but with no marked improvement (106). 
The unsuccessful ligation reactions may be due to poor digestion of the ClaI-site in the 
insert, since this restriction site is approximately 10 bp to the 3’-end of insert (Fig 4.2).  
Fig 4.2 The nucleotide sequence of the final PCR product (insert). The sakacin P leader sequence is 
outlined in blue, the plnE-gene is outlined in red and the plnI-gene is outlined in green. The restriction 
sites for MluI and ClaI are outlined and underlined in purple and orange, respectively.  
 
Generally, a cleavage site should not be located too close to the end of the linear DNA 
in order to obtain efficient cleavage (97). Sub-cloning into the pGEM®-T Easy Vector, 
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using the principle of TA-cloning, was shown to circumvent this problem (106). For 
that reason, sub-cloning into the pGEM®-T Easy Vector was also used in this study. 
The insert was treated with Taq DNA Polymerase (Fermentas) to create 3’ terminal 
deoxyadenosine overhangs (section 3.3.5) prior to ligation (section 3.2.6) into the 
pGEM®-T Easy Vector. The ligation reaction was transformed into DH5α cells (section 
3.1.2) and grown on LB agar plates in the presence of ampicillin for selection (section 
3.1.5). Plasmids from isolated clones (section 3.2.2) were screened for insert by double 
restriction digestion with MluI and ClaI and verified by DNA sequence analysis (section 
3.2.7). The restriction digestion produced the correct size of insert (results not shown). 
In two separate solutions, the pGEM®-T Easy Vector containing the correct insert and 
the pLT100β plasmid (a pLPV111 derivative) were treated with a double restriction 
digestion with MluI and ClaI and screened by gel electrophoresis (results not shown). 
The band corresponding to the correct size of insert and the band corresponding to the 
linear pLPV111 plasmid were excised from the gel and purified with a GFX kit. The 
insert was then ligated into the pLPV111 plasmid using 1:1, 3:1 and 5:1 insert:plasmid 
molar ratios and transformed into DH5α cells. The cells were grown on LB agar plates 
in the presence of erythromycin. Purified plasmids with insert were verified by DNA 
sequencing. The insert turned out to be correctly ligated with the exception of a silent 
mutation in the codon for glutamic acid, position 218 (E218), in the plnI-gene. 
4.2 Construction of the Peptide Variants  
Both CD and NMR analysis have shown that plantaricin EF induces helical structuring 
when exposed to membrane-like entities such as micelles and negatively charged 
liposomes (3, 58). As described in section 1.5.4, all two-peptide bacteriocins 
characterized to date contain GxxxG motifs (27). To investigate the importance of the 
GxxxG motifs in plantaricin EF, point mutations were introduced by site-directed 
mutagenesis in the two GxxxG motifs of the PlnE peptide, G5xxxG9 and G20xxxG24. 
The glycine residues were substituted one at a time in both motifs with alanine, serine, 
lysine, glutamine, leucine and isoleucine residues. Also, in order to see how the 
structure of the membrane-bound plantaricin EF was affected by the tyrosine residue in 
PlnE (Y6; Fig 4.3), substitutions with the amino acids tryptophan, phenylalanine, 
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leucine and arginine were performed. Fig 4.3 demonstrates the nucleotide and amino 
acid sequences of the PlnE peptide fused to the sakacin P leader sequence (upper row). 
The G5xxxG9 and the G20xxxG24 motifs are marked with grey background and the 
mutation sites are marked in green. All the mutated peptides were assigned a name 
based on the original amino acid, position and the substituted amino acid. If, for 
instance, a glycine residue at position 5 is exchanged with an alanine residue, the 
mutated peptide is termed ‘G5A’.   
atggaaaagtttattgaattatctttaaaagaagtaacagcaattacaggtgga  
M  E  K  F  I  E  L  S  L  K  E  V  T  A  I  T  G  G   
            5  6        9 
tttaatcggggcggttataactttggtaaaagtgttcgacatgttgttgatgca 
F  N  R  G  G  Y  N  F  G  K  S  V  R  H  V  V  D  A   
   20          24      
attggttcagttgcaggcattcgtggtattttgaaaagtattcgt taa 
I  G  S  V  A  G  I  R  G  I  L  K  S  I  R   STOP 
Fig 4.3 Nucleotide and amino acid sequences of PlnE and the sakacin P leader sequence. The 
sakacin P leader sequence is displayed in the upper row followed by the PlnE peptide. The two GxxxG 
motifs are marked with grey background. The tyrosine residue is at position 6 and all mutation sites are 
marked in green.  
 
A total of 28 mutants were constructed by in vitro site-directed mutagenesis (section 
3.3.4). The PCR product was treated with DpnI to digest the methylated parental 
plasmid DNA (section 3.2.5) and transformed into DH5α cells and subsequently grown 
on LB plates containing erythromycin (section 3.1.5). Purified plasmids were sequenced 
for verification and 27 out of 28 mutations were confirmed. The only mutation not 
possible to verify was the substitution of Y6 with a tryptophan residue (i.e. the Y6W 
mutation). Table 4.1 summarizes the constructions, transformations and verification by 
sequencing of the mutated pPlnE100 plasmids. Two sequencing primers specific for the 
pLPV111 plasmid were used (Appendix, section 6.4.1), pLPV111sekF and 
pLPV111sekR (both from Eurogentec S.A.). They anneal to each strand of the plasmid 
upstream the restriction sites for ClaI and MluI, respectively. All the mutagenic primers 
are listed in the Appendix, section 6.4.2.  
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Table 4.1 Construction, transformation and verification by DNA sequencing of the mutated 
pPlnE100 plasmids: 
Mutation  
PCR product of 
mutated pPlnE100 
observed on agarose 
gel 
Mutated pPlnE100 transformed 
into E. coli DH5α as observed 
on agarose gel 
Mutated 
pPlnE100 
verified by 
sequencing 
G5xxxG9 Motif  
G5A + + + 
G5S + + + 
G5K + + + 
G5Q + + + 
G5L + + + 
G5I + + + 
G9A + + + 
G9S + + + 
G9K + + + 
G9Q + + + 
G9L + + + 
G9I + + + 
’+’/’-‘ Designates that the work has been accomplished/not accomplished. 
* Not possible to verify the mutation Y6W by DNA sequencing due to large noise in peak reading. 
G20xxxG24 Motif  
G20A + + + 
G20S + + + 
G20K + + + 
G20Q + + + 
G20L + + + 
G20I + + + 
G24A + + + 
G24S + + + 
G24K + + + 
G24Q + + + 
G24L + + + 
G24I + + + 
Tyrosine Residue  
Y6L + + + 
Y6R + + + 
Y6F + + + 
Y6W + + -* 
Total 28 28 27 
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4.3 Production of the Peptide Variants 
The peptides were produced by the use of the heterologous expression system L. sakei 
Lb790/pSAK20/pPlnE100 (section 3.5.1).  When all the purified pPlnE100 plasmids 
containing the desired mutated plnE-gene had been verified by sequencing, they were 
transformed into competent L. sakei Lb790/pSAK20 cells by electroporation (section 
3.1.4). Successfully transformed cells were grown on MRS plates containing the 
appropriate antibiotics for selection of pPlnE100 and pSAK20 (section 3.1.5). Agarose 
gel electrophoresis accompanied by DNA sequence analysis with purified pPlnE100 
plasmids from L. sakei Lb790/pSAK20 cells verified that the cells had been transfected 
with the correct plasmid (results not shown; see Table 4.3, section 4.4.4 for an overview 
of all constructed mutants).  
4.4 Purification and Analysis of the Peptide Variants 
The purification steps and all downstream applications in this thesis were performed 
with the wild type PlnE and PlnF peptides as well as peptides with mutations in the 
G5xxxG9 motif with the exception of the mutation G9I, which was only purified.  
4.4.1 The Two-Step Purification Procedure 
The first of two purification steps carried out on wild type and mutant PlnE peptides 
was performed by the use of cation-exchange chromatography (section 3.5.3). All eluted 
peptides were confirmed present in activity measurements upon complementation with 
wild type PlnF. The peptides were further purified by reverse-phase chromatography 
(section 3.5.4) where the UV absorbance was recorded at 214 nm and 280 nm. A 
representative collection of chromatograms is shown in Figs 4.4 to 4.8. All the peptides 
eluted between 38.5% and 42% 2-propanol. Correctly mutated peptides were verified by 
MS analysis.  
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Fig 4.4 Reverse-phase chromatogram of the PlnE peptide. The PlnE peptide eluted at approximately 
39% 2-propanol. The correct peak (i.e. fraction with antimicrobial activity) is indicated with vertical, 
stapled lines. The absorbance-scale (i.e. milli absorbance units (mAU)) on the vertical axis represents 
both 214 nm and 280 nm. The horizontal scale represents the elution volume (V) in ml. Confirmation of 
true identity was verified by MS analysis and activity measurements.  
 
 
 
 
Fig 4.5 Reverse-phase chromatogram of the G5A peptide. The G5A peptide eluted at approximately 
39% 2-propanol. See Fig 4.4 for description of chromatogram. 
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Fig 4.6 Reverse-phase chromatogram of the G5K peptide. The G5K peptide eluted at approximately 
38.5% 2-propanol. See Fig 4.4 for description of chromatogram. 
 
 
 
 
 
Fig 4.7 Reverse-phase chromatogram of the G9A peptide. The G9A peptide eluted at approximately 
40% 2-propanol. See Fig 4.4 for description of chromatogram. 
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Fig 4.8 Reverse-phase chromatogram of the G9Q peptide. The G9Q peptide eluted at approximately 
39% 2-propanol. See Fig 4.4 for description of chromatogram.  
 
4.4.2 Mass Determination  
MALDI-TOF MS (section 3.5.6) was used to analyze if the samples contained the 
desired wild type or mutant PlnE peptides. The measured molecular masses of all the 
collected compounds are shown in Table 4.2 and were in good agreement with the 
theoretical masses.  
Table 4.2 The theoretical and detected masses of the wild type and mutant PlnE peptides: 
Peptide Theoretical mass (Da) Detected mass (Da) 
PlnE 3545 3544 
G5A 3559 3558 
G5S 3575 3574 
G5K 3616 3615 
G5Q 3616 3615 
G5L 3601 3600 
G5I 3601 3600 
G9A 3559 3558 
G9S 3575 3574 
G9K 3616 3615 
G9Q 3616 3615 
G9L 3601 3600 
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4.4.3 Degree of Purity 
The purification analysis of the wild type and peptide variants of PlnE was performed 
by analytical reverse-phase chromatography using the SMART system (Amersham 
Biosciences) as described in section 3.5.5. A collection of chromatograms is shown in 
Figs 4.9 to 4.12. The peptides eluted between 30% and 36% (v/v) 2-propanol/0.1% (v/v) 
TFA and the fractions were subsequently analyzed by MS for verification of correct 
peptide. Usually, a volume of 200 µl sample was diluted with 800 µl dH2O/0.1% (v/v) 
TFA to decrease the concentration of 2-propanol before applying to the column. Judged 
by the chromatograms, most of the peptides were estimated to have a purity of over 
70% except for the mutant G9A which was estimated to have a purity of approximately 
50% because of a second peak (as well as two other small peaks in front) eluting close 
to the putative G9A peptide peak with no baseline separation (Fig 4.12). The mass 
spectra obtained from these fractions of the G9A solution showed, however, no other 
components in the sample other than the G9A peptide and hence the purity is probably 
higher than initially assumed.  
 
 
Fig 4.9 Analytical reverse-phase chromatogram of the PlnE peptide using the SMART system. 
The PlnE peptide eluted at approximately 30% 2-propanol. The absorbance-scale (i.e. absorbance units 
(AU)) represents the absorbance at 214 nm and the horizontal scale represents the elution volume (V) in 
ml.  
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Fig 4.10 Analytical reverse-phase chromatogram of the G5A peptide using the SMART system. 
The G5A peptide eluted at approximately 35% 2-propanol. See Fig 4.9 for description of 
chromatogram.  
 
 
 
 
 
Fig 4.11 Analytical reverse-phase chromatogram of the G5K peptide using the SMART system. 
The G5K peptide eluted at approximately 30% 2-propanol. See Fig 4.9 for description of 
chromatogram. 
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Fig 4.12 Analytical reverse-phase chromatogram of the G9A peptide using the SMART system. 
Several peaks were obtained. The G9A peptide eluted at approximately 32.5% 2-propanol (the peak 
with most absorbance), whereas the second largest peak eluted at approximately 31.5% 2-propanol. See 
Fig 4.9 for description of chromatogram. 
 
4.4.4 Summary of Constructs and Purified Peptide Variants of PlnE 
The 24 mutated pPlnE100 plasmids constructed based on the two GxxxG motifs in PlnE 
were transformed into L. sakei Lb790/pSAK20 cells and verified by DNA sequencing. 
Peptide expression of the 12 variants based on the G5xxxG9 motif was verified by MS 
analysis as well as confirmation of activity in bacteriocin activity assays, except for the 
mutant G9I which was not applied in activity assays. With the exception of the mutation 
Y6W, all mutated pPlnE100 plasmids constructed based on the tyrosine residue were 
transformed into E. coli DH5α cells and verified by DNA sequencing. Table 4.3 
summarizes confirmed transformations, peptide expression, and verification by MS 
analysis and activity assays of all the PlnE variants that were constructed.  
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Table 4.3 An overview of the pathway from transformation into cells to verification of peptide 
expression by MS analysis and activity assays: 
M
ut
at
io
n 
Verified 
transfor- 
mation 
into E. 
coli 
DH5α 
Transfor- 
med into 
L. sakei 
Lb790/ 
pSAK20 
Verified 
by 
sequence 
Purified 
peptide 
Verified 
by MS 
Confir- 
med 
activity 
with 
assays 
Analyzed 
degree of 
purity 
G5xxxG9 Motif  
G5A + + + + + + + 
G5S + + + + + + + 
G5K + + + + + + + 
G5Q + + + + + + + 
G5L + + + + + + + 
G5I + + + + + + + 
G9A + + + + + + + 
G9S + + + + + + + 
G9K + + + + + + + 
G9Q + + + + + + + 
G9L + + + + + + + 
G9I + + + + + -a) - 
G20xxxG24 Motif  
G20A + + + -b) - - - 
G20S + + + - - - - 
G20K + + + - - - - 
G20Q + + + - - - - 
G20L + + + - - - - 
G20I + + + - - - - 
G24A + + + - - - - 
G24S + + + - - - - 
G24K + + + - - - - 
G24Q + + + - - - - 
G24L + + + - - - - 
G24I + + + - - - - 
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Table 4.3 continued: 
M
ut
at
io
n 
 
Verified 
transfor- 
mation 
into E. 
coli 
DH5α 
Plasmids 
transfor- 
med into 
L. sakei 
Lb790/ 
pSAK20 
Verified 
by 
sequence 
Purified 
peptide 
Verified 
by MS 
Confir- 
med 
activity 
with 
assays 
Analyzed 
degree of 
purity 
Tyrosine Residue  
Y6L + -c) - - - - - 
Y6R + - - - - - - 
Y6F + - - - - - - 
Y6W - - - - - - - 
Total 27  24  24  12  11  11 11 
’+’/’-’ Designates that the work has been accomplished/not accomplished. 
a) The mutant G9I was not included in activity assays. 
b) The mutated pPlnE100 plasmids constructed based on the G20xxxG24 motif were only confirmed 
properly transformed into L. sakei Lb790/pSAK20. 
c) The mutated pPlnE00 plasmids constructed based on the tyrosine residue (mutations Y6L, Y6R and 
Y6F, not Y6W) were only confirmed properly transformed into E. coli DH5α (as verified by DNA 
sequencing).  
 
4.4.5 Estimated Peptide Concentrations 
As described in section 3.5.7, the OD at 214 nm of the wild type and mutant peptides of 
PlnE were estimated based on their peak areas from chromatograms obtained by 
reverse-phase chromatography using the ÄKTA system. This was done because almost 
none of the mutant peptides had high enough concentrations to be measured at an 
absorbance of 280 nm. The extinction coefficient of PlnE at 214 nm was calculated to 
be approximately 50000 M-1cm-1 and it was assumed that this value would also hold 
true for the mutant peptides. Consequently, the concentration of all peptides was 
calculated by the use of this extinction coefficient and their OD at 214 nm. The results 
are listed in Table 4.4.  
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Table 4.4 Measured absorbance at 214 nm for the wild type and peptide variants of PlnE and 
their calculated concentrations as well as the amount of peptide isolated per L cell culture: 
Peptide A214a) 
Concentration 
(µM) 
Amount peptide 
isolated per L cell 
culture (µg) 
PlnE 0.6 12 190 
G5A 0.3 6 90 
G5S 0.1 2 15 
G5K 0.05 1 10 
G5Q 0.5 10 100 
G5L 0.07 1 13 
G5I 0.2 4 40 
G9A 0.2 4 40 
G9S 0.3 6 60 
G9K 0.05 1 8 
G9Q 0.2 4 130 
G9L 0.4 8 110 
a) The UV absorbance of each peptide at 214 nm based on the peak area from the respective 
chromatograms obtained using the ÄKTA system. 
 
 
4.5 Bacteriocin Activity Assays 
The bacteriocin activity assays were performed as described in section 3.5.8. A purified 
wild type PlnF peptide (known to be devoid of contaminants) obtained from a previous 
study by Fimland et al. (61) was used in all assays performed on the mutant PlnE 
peptides.   
4.5.1 Finding Suitable Indicator Strains 
Several different indicator strains were assayed against wild type PlnE and PlnF to find 
a suitable indicator strain with high sensitivity toward the bacteriocin. The results are 
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listed in Table 4.5 as well as the incubation conditions for all the indicator strains tested. 
Three independent parallels were used. The two most sensitive indicator strains, 
Lactobacillus viridescens NCDO 1655 and Lactobacillus curvatus 89 LMGT 2355, 
were chosen to evaluate activity of the different mutant PlnE peptides.  
Table 4.5 Possible indicator strains tested against PlnE+PlnF: 
Organism Strain Mean MIC valuea) 
(nM) 
Incubation 
conditions 
Carnobacterium piscicola LMGT 2332        430 
 
MRS medium, 
ON 
Lactobacillus corynifornis ssp. 
Torquens  
NCDO 2740        30 
 
MRS medium, 6 
hours 
Lactobacillus curvatus 89  LMGT 2355        1 
 
MRS medium, 6 
hours 
Lactobacillus plantarum 965  LMGT 2003        5 
 
MRS medium, 6 
hours 
Lactobacillus sakei  NCDO 2714        20 
 
MRS medium, 
ON 
Lactobacillus viridescens  NCDO 1655        2 
 
MRS medium, 6 
hours 
Lactococcus LMGT 2077        160 
 
GM17b) medium, 
ON 
Lactococcus lactis  MG 1363        180 
 
GM17b) medium, 
6 hours 
Lactococcus lactis  IL 1403        170 
 
GM17b) medium, 
6 hours 
Pediococcus acidilactici  LMGT 2351        30 
 
MRS medium, 6 
hours 
Pediococcus acidilactici  NCDO 521        30 
 
MRS medium, 
ON 
Pediococcus acidilactici NCDO 1859        400 
 
MRS medium, 6 
hours 
Pediococcus pentosaceus  NCDO 990        50 
 
MRS medium, 
ON 
Pediococcus pentosaceus FBB 
63 B 
LMGT 2722        400 
  
 
MRS medium, 6 
hours 
a) The MIC value is defined as the concentration of the wild type PlnE that inhibits the growth of the 
indicator strain by 50% when PlnE is present together with a molar excess of PlnF. 
b) M17 broth supplemented with 0.4% (v/v) glucose and 0.1% (v/v) Tween 80.  
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4.5.2 Bacteriocin Activity of Peptide Variants of PlnE Assayed Against 
Lactobacillus viridescens NCDO 1655 
The indicator strain Lactobacillus viridescens NCDO 1655 was assayed against the 
mutant PlnE peptides complemented with wild type PlnF. The wild type PlnE+PlnF 
combination was also assayed for comparison. The results are listed in Table 4.6 and the 
MIC values represented are obtained from three independent parallels.  
Assaying the combinations G9K+PlnF and G9S+PlnF resulted in a 30 to 60 fold 
reduction in activity, whereas the G9L+PlnF combination caused a 150 fold reduction in 
activity compared to the wild type combination. The combination G9Q+PlnF was 
highly detrimental as the activity was reduced by over 300 times. Reasonably well 
tolerated combinations (3 to 13 fold reduction in activity) were also observed: 
G9A+PlnF, G5K+PlnF, G5L+PlnF and G5I+PlnF. Interestingly, the G5A+PlnF 
combination resulted in an approximately 2 fold increase in activity compared to the 
wild type combination. G5S+PlnF resulted in a similar activity as the wild type 
combination.  
When comparing equivalent amino acid changes in the G5 position versus the G9 
position in the G5xxxG9 motif, changes in the G9 position seemed to have the most 
detrimental effect on activity toward the indicator strain when combined with wild type 
PlnF. 
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Table 4.6 MIC values of mutant PlnE peptides complemented with PlnF assayed against 
Lactobacillus viridescens NCDO 1655: 
Peptidea) MIC value (nM)b) MIC(mut)
c) 
MIC(wt) 
PlnE+PlnF 0.1/0.2/0.5 1 
G5A+PlnF 0.1/0.1/0.2 0.5 
G5S+PlnF 0.2/0.1/0.3 0.8 
G5K+PlnF 2/3/3 10 
G5Q+PlnF 20/40/30 100 
G5L+PlnF 0.7/1/1 3 
G5I+PlnF 1/2/2 6 
G9A+PlnF 3/3/4 13 
G9S+PlnF 16/14/18 60 
G9K+PlnF 8/6/7 30 
G9Q+PlnF 100/80/110 360 
G9L+PlnF 40/40/40 150 
a) A purified PlnF peptide from a previous study by Fimland et al. (61) was used in all mutant peptide 
assays. 
b) The MIC value is defined as the concentration of the wild type or peptide variants of PlnE that inhibits 
the growth of the indicator strain by 50% when one of these variants or wild type PlnE are present 
together with a molar excess of PlnF. The three values in each row represent the MIC value from three 
independent parallels. 
c) The mean MIC value of the mutant peptide divided by the mean MIC value of the wild type PlnE 
peptide. This is a relative value which indicates the difference in activity of the mutant peptide 
compared to the wild type peptide, normally as an ‘X’ fold reduction in activity where ‘X’ is the 
relative value. 
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4.5.3 Bacteriocin Activity of Peptide Variants of PlnE Assayed Against 
Lactobacillus curvatus 89 LMGT 2355 
The indicator strain Lactobacillus curvatus 89 LMGT 2355 was also assayed against the 
mutant peptides complemented with wild type PlnF. Only two independent parallels 
were run for each combination. Although three independent parallels is normally the 
minimum required for a good quantitation of results, the two independent parallels of 
each mutant peptide confirmed a quite similar value. As an example, the peptide 
combination G5L+PlnF had a MIC value of 0.1 the first day and a value of 0.3 the next 
day. An exception was the PlnE+PlnF combination which had a MIC value of 0.02 the 
first day and a value of 0.2 the next day (a 10 times increase in MIC value). The results 
are listed in Table 4.7. 
The G9L+PlnF and the G9Q+PlnF combinations were the most detrimental, resulting in 
180 to 600 fold reduction in activity, respectively. The only G5 mutant that was not well 
tolerated was G5Q which, when complemented with PlnF, resulted in a 120 fold 
reduction in activity. Other G5 mutants (G5S, G5K, G5L and G5I), as well as the G9A 
mutant, were reasonably well tolerated when complemented with PlnF, causing only 2 
to 9 fold reduction in activity. Regarding the rest of the G9 mutant combinations, 
G9K+PlnF and G9S+PlnF resulted in a 40 to 70 fold reduction in activity, respectively. 
Although assayed only once with this indicator strain, the G5A+PlnF combination 
showed a 4 fold increase in activity compared to PlnE+PlnF, approximately equal to the 
results observed for the same combination assayed against the indicator strain 
Lactobacillus viridescens NCDO 1655 (Table 4.6).  
Compared to the other indicator strain (section 4.5.2), the observations indicates again 
that the amino acid substitutions in the G9 position results in a higher loss of activity 
compared to the equivalent changes in the G5 position. 
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Table 4.7 MIC values of mutant peptides complemented with PlnF assayed against Lactobacillus 
curvatus 89 LMGT 2355: 
Peptidea) MIC value (nM)b) MIC(mut)
c) 
MIC(wt) 
PlnE+PlnF 0.02/0.2 1 
G5A+PlnF <0.01/0.04d) 0.4 
G5S+PlnF 0.2/0.2 2 
G5K+PlnF 1/1 9 
G5Q+PlnF 14/13 120 
G5L+PlnF 0.1/0.3 2 
G5I+PlnF 0.1/0.5 3 
G9A+PlnF 1/1 9 
G9S+PlnF 7/8 70 
G9K+PlnF 4/5 40 
G9Q+PlnF 60/70 600 
G9L+PlnF 18/22 180 
a) A purified PlnF peptide from a previous study by Fimland et al. (61) was used in all mutant peptide 
assays. 
b) The MIC value is defined as the concentration of the wild type or peptide variants of PlnE that inhibits 
the growth of the indicator strain by 50% when one of these variants or wild type PlnE are present 
together with a molar excess of PlnF. The two different values indicate the measured MIC values from 
two independent parallels. 
c) The mean MIC value of the mutant peptide divided by the mean MIC value of the wild type peptide. 
This is a relative value which indicates the difference in activity of the mutant peptide compared to the 
wild type peptide, normally as an ‘X’ fold reduction in activity where ‘X’ is the relative value. 
d) Assaying the G5A peptide resulted in only one measurable MIC value because of high activity. 
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5. Discussion 
5.1 Production and Purification of Wild Type and Peptide 
Variants of PlnE 
A total of 28 mutated pPlnE100 plasmids – 24 involving replacement of the glycine 
residues in the two GxxxG motifs and 4 involving replacement of the tyrosine residue in 
position 6 – were constructed by the use of in vitro site-directed mutagenesis and were 
successfully transformed into E. coli DH5α cells (Table 4.1). All mutations, except for 
the Y6W mutation, were verified by DNA sequencing. The Y6W mutation was 
performed three times by site-directed mutagenesis and the putative constructs were 
transformed into E. coli DH5α cells more than four times. In all the sequencing results 
obtained with the Y6W construct, large background noise masked all attempts to 
confirm the correct mutated sequence. Because of time limitations, it was decided to 
focus the subsequent work on mutations involving the two putative helix-helix 
interacting GxxxG motifs in PlnE. The 24 mutated variants involving these two motifs 
were transformed into L. sakei Lb790/pSAK20 cells and verified by DNA sequencing 
(Table 4.3). For the subsequent purification and activity measurements, it was decided 
(again, because of time limitations) to focus on the 11 peptide variants in which the 
glycine residues in the G5xxxG9 motif were individually substituted. The G9I mutant 
was not included, since it is expected that the G9L and the G9I mutants will affect the 
growth inhibition of sensitive cells in a similar manner due to similar/comparable side 
chain properties. Correctly introduced mutations were verified by DNA sequencing and 
by MS analysis after purification of the peptides (Table 4.3).  
The amount of mutant peptides isolated per 1 L cell culture varied from less than 20 µg 
(as was the case for the mutants G5S, G5K, G5L and G9K) to 100-130 µg for the 
mutants G5Q, G9Q and G9L (Table 4.4). The wild type PlnE peptide resulted in a yield 
of approximately 200 µg. The low yield of some of the mutant peptides can be due to 
low expression in the host cell and/or poor secretion by the transport machinery. Low 
yields may also have been due to loss of peptides upon purification. For instance, 
overloading the cation-exchange column in the first purification step, resulting in 
peptides simply passing through the column, may have contributed to the low yield. 
Discussion   
74 
 
Some activity was indeed detected in the ‘flow-through’ fractions, which might be 
indicative of a saturated column. In a recent study, cation-exchange chromatography of 
the PlnF peptide resulted in only a 2% yield in the absence of 2-propanol in the elution 
buffer (106), whereas a yield of 40% was obtained in the presence of 20% (v/v) 2-
propanol (Oppegård, C., personal communication). There was no further increase in the 
yield upon increasing the percentage of 2-propanol to 60%. Based on these results, 2-
propanol was in this study added to a final concentration of 20% to the elution buffer 
used upon cation-exchange chromatography. It is not clear why 2-propanol increases the 
yield of PlnF (and presumably also PlnE). Increased hydrophobicity of eluent might 
prevent (or disrupt) aggregation of peptides on the column.  
The measured peak areas at an absorbance of 214 nm were used for estimating the 
concentration of purified peptides (section 4.4.5). At this wavelength, however, there 
are several other substances, such as caramelized sugar from the medium and 2-
propanol, that also absorbs light and this may lead to an over-estimation of the amount 
of peptides. This will in turn lead to an under-estimation of the specific antimicrobial 
activity. Moreover, some of the mutant peptides resulted in only small peaks, even at 
214 nm (e.g. the mutations G5K (Fig 4.6), G5I and G9K), which further complicates 
quantitation of the purified peptides, which in turn leads to uncertainties in the MIC 
values.   
5.2  Effects of the G5xxxG9 Mutations on Bacteriocin Activity  
When the wild type PlnE and PlnF combinations (both of which were purified in this 
study) were initially assayed in search for sensitive indicator strains (Table 4.5), a 
significantly higher MIC value (approximately 10 times higher) was obtained than the 
MIC values subsequently obtained for the wild type combination when the mutant 
peptides were assayed (Tables 4.6 and 4.7). The high MIC value obtained initially 
(Table 4.5) might be due to an over-estimation of the calculated concentration of PlnF 
that was used in the initial assay. This may in turn have resulted in the actual 
concentration of PlnF being too low. If the amount of PlnF applied in the activity assay 
was less than the amount of PlnE, then some of the PlnE peptides will lack a PlnF-
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interacting partner and will thus not be active. Consequently, a higher MIC value of 
PlnE would be determined in these assays (Table 4.5).   
A total of 11 peptide variants with replacements in one of the two glycine residues in 
the G5xxxG9 motif were assayed against two different indicator strains (Tables 4.6 and 
4.7). Similar results were obtained with both indicator strains, which increase the 
credibility of the measurements. However, additional indicator strains should eventually 
be included in order to ascertain that the results obtained are not strain-dependent, as it 
has been observed that the effect of mutation on bacteriocin activity may in some cases 
depend on the indicator strains used (107-109). The fact that similar results were 
obtained with the two indicator strains indicate that they are not atypical, as it is 
unlikely that both strains show unusual behaviour.  
Substituting glycine residues in a helix-helix interacting GxxxG motif with a large 
amino acid residue is expected to have a negative impact on the bacteriocin activity as 
there is close contact between the polypeptide backbones of the two α-helices at these 
positions. Furthermore, these glycine residues are expected to be in the hydrophobic 
core of the membrane, since a hydrophobic environment will strengthen the interhelical 
hydrogen bond between the Cα hydrogen atom of a glycine residue and a backbone 
carbonyl oxygen atom on the opposite α-helix. Two putative helix-helix interacting 
models have been proposed (a parallel and an anti-parallel) for the two-peptide 
bacteriocin plantaricin EF upon interaction with target-cell membranes (Fig 5.1) (85). In 
both models, the G5xxxG9 motif in PlnE will interact with the flat surface of PlnF 
formed by residues S16, G19 and P20. A third possible model entails that the G30xxxG34 
motif in PlnF interacts with the G5xxxG9 motif in PlnE in a parallel manner (in an anti-
parallel manner, the two negatively charged aspartate residues D17 in PlnE and D22 in 
PlnF would come close to each other) (61).  
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Fig 5.1 Two putative helix-helix interacting models of plantaricin EF. A) PlnE and PlnF interact in a 
parallel manner where the G20xxxG24 motif in PlnE interacts with the G30xxxG34 motif in PlnF, enabling 
the G5xxxG9 motif in PlnE to come in close contact with the flat surface of PlnF from residue S16 to 
P20, thereby creating increased opportunities for charge-charge interactions between the two peptides. 
B) PlnE and PlnF interact in an anti-parallel manner where the G5xxxG9 motif in PlnE interacts with the 
flat surface of PlnF from residue S16 to P20. This will allow for increased charge-charge interactions 
between the two peptides. Black characters indicate hydrophobic residues, red indicates positively 
charged hydrophilic residues (K10 in PlnE in B is supposed to be marked as red), blue indicates 
negatively charged hydrophilic residues, and green indicates neutral hydrophilic residues. The potential 
interactions involving the GxxxG motifs are boxed in with dotted lines and the possible charge-charge 
interactions are indicated with dotted lines. The figure is adapted from Rogne, P., 2009 (85). 
 
The results in Tables 4.6 and 4.7 suggest that the G5xxxG9 motif in PlnE is probably not 
part of a helix-helix interacting GxxxG motif between PlnE and PlnF. This conclusion is 
mainly based on the results obtained with the glycine residue in position 5 (G5), which 
does not seem to be surrounded by any spatial constraints. When G5 was substituted 
with large hydrophobic residues (leucine and isoleucine), the bacteriocin activity was 
only marginally reduced (2-6 fold). The results also indicate that G5 is located in a 
hydrophobic environment, since replacement with a large hydrophilic residue 
(glutamine) was (in contrast to replacements with leucine and isoleucine) very 
detrimental (about 100 fold reduction in activity). Replacement with a large positively 
charged residue (lysine) was, however, relatively well tolerated (about 10 fold 
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reduction; see below at the end of next page for a possible explanation why lysine has a 
less detrimental effect than glutamine). Substituting G5 with serine or alanine residues 
resulted in activity almost as good as, or better than the wild type activity. 
In contrast to G5, the glycine residue at position 9 (G9) seems sterically restricted, since 
substituting G9 with a large hydrophobic (leucine) residue and especially with a large 
hydrophilic (glutamine) residue was highly detrimental (although the positively charged 
lysine residue was, again, more tolerated than the glutamine residue). This suggests that 
the peptide backbone is, at this position, in close contact with another peptide/protein – 
possibly PlnF and/or a plantaricin EF docking protein. It also seems that G9 is 
positioned in a hydrophobic environment, since replacement of G9 with the small 
hydrophobic residue alanine was less detrimental than replacement with the small 
hydrophilic residue serine (about 10 fold reduction in activity compared to 60-70 fold 
reduction). These results seem to be in a somewhat ‘contrast’ to what was observed with 
the four glycine residues in two helix-helix interacting GxxxG motifs in lactococcin G 
(72): both large hydrophobic and large hydrophilic residues resulted in a quite similar 
detrimental effect on activity (as was also observed in this study for G9 in PlnE), 
whereas the glycine to alanine and serine mutations caused a relatively low reduction in 
activity (72). It was thus suggested that it was the size of the side chain residues that 
was the major cause of reduced activity, rather than the polarity of the residues (72). 
The glycine residue at position 9 in the PlnE peptide, however, seems to be highly 
affected by the size of the side chains, but also (although to a lesser extent) by the 
polarity of the side chains.  
The replacement of G5 and G9 with the large and hydrophilic, positively charged lysine 
residue was less detrimental than replacement with the somewhat smaller, but neutral 
glutamine residue. An explanation could be that the presumably negative impact the 
lysine residue may have on the structuring of PlnE is partly counteracted by the 
conceivably positive effect it might have on the initial binding of PlnE to the negatively 
charged bacterial membrane. Indeed, mutations in the pediocin-like bacteriocin sakacin 
P, which increased the net positive charge by one, resulted in an increased binding to 
the target-cell membrane and the antimicrobial activity was about the same as or better 
than that of wild type sakacin P (107). 
Discussion   
78 
 
The results obtained do not discriminate between the two putative models in Fig 5.1, but 
they do not support the third proposed model, in which the G30xxxG34 motif in PlnF 
interacts with the G5xxxG9 motif in PlnE in a parallel manner, since the glycine residue 
at position 5 is not sterically restricted — a property not compatible with the formation 
of favourable contact between two transmembrane α-helices.   
5.3 Future Aspects 
A total of 21 PlnF variants, in which tryptophan and tyrosine residues and the glycine 
residues in the G30xxxG34 motif are substituted, have been constructed in our lab. 
Purification and activity measurements of these PlnF variants as well as all the mutant 
PlnE peptides that were constructed in this study are in progress. Determining the effect 
all of these mutations have on the bacteriocin activity should give a more complete 
picture of the interaction between PlnE and PlnF as well as the orientation of the 
plantaricin EF complex in target-cell membranes. Especially the effect of mutations in 
the G20xxxG24 motif in PlnE and the G30xxxG34 motif in PlnF should discriminate 
between the two models presented in Fig 5.1. If individual replacements with large 
residues in these two motifs, and especially if combinations of mutated variants of these 
motifs, are highly detrimental, then this will be an indication that these motifs are 
involved in an interpeptide helix-helix interaction, in support of the model presented in 
Fig 5.1 A.  
Because of the uncertainties involving the estimated amount of mutant PlnE peptides 
and their calculated concentrations, all the mutant peptides constructed for the G5xxxG9 
motif should be purified and assayed for confirmation of results obtained in this study.  
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6. Appendix 
6.1 Amino Acids 
Single and three letter abbreviation for the amino acids: 
Symbol Abbreviation Amino Acid 
A Ala Alanine 
C Cys Cysteine 
D Asp Aspartic acid 
E Glu Glutamic acid 
F Phe Phenylalanine 
G Gly Glycine 
H His Histidine 
I Ile Isoleucine 
K Lys Lysine 
L Leu Leucine 
M Met Methionine 
N Asn Asparagine 
P Pro Proline 
Q Gln Glutamine 
R Arg Arginine 
S Ser Serine 
T Tyr Tyrosine 
V Val Valine 
W Trp Tryptophan 
Y Tyr Tyrosine 
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Chemicals and manufacturers: 
 
6.2 Chemicals, Kits and Equipment 
 
  
Chemicals Manufacturer 
 Agar Merck 
 Agarose Merck 
 Ampicillin CALBIOCHEM 
 ATP Amersham Biosciences 
 100 bp DNA ladder Fermentas 
 100 bp DNA ladder plus Fermentas 
 CaCl2 Merck 
 Chloramphenicol Sigma 
 dNTPs (dATP, dCTP, dGTP, dTTP) Pharmacia Biotech 
 DpnI  Fermentas 
 Erythromycin Sigma 
 Ethidium bromide Amersham Biosciences 
 Ethylenediaminetetraacetic acid (EDTA) Sigma 
 Glacial acetic acid KEBO 
 Glucose Sigma 
 Glycerol VWR 
 Glycine Sigma 
 1 kb DNA ladder Fermentas 
 6xLoading Dye Solution Fermentas 
 MgCl2 AppliChem 
 MgSO4 Fermentas 
 MRS broth  OXOID 
 M17 broth OXOID 
 NaCl VWR 
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 NaH2PO4 PROLABO 
 Na2HPO4 Merck 
 Peptone Sigma-Aldrich 
 Pfu DNA Polymerase buffer Fermentas 
 Pfu DNA Polymerase Fermentas 
 PfuTurbo DNA Polymerase Stratagene 
 Polyethylene glycol (PEG) Merck  
 2-propanol Sigma-Aldrich 
 SP-Sepharose Fast Flow GE Healthcare 
 Taq DNA Polymerase buffer Fermentas 
 Taq DNA Polymerase Fermentas 
 Trifluoroacetic acid (TFA) Merck 
 Tris base Angus Buffers and Biochemicals 
 Yeast Extract Merck 
 
Kits and manufacturers: 
Kits Manufacturer 
illustra GFXTM PCR DNA and Gel Band Purification Kit GE Healthcare 
DNeasy® Tissue Kit QIAGEN 
NucleoSpin® Tissue Kit Macherey-Nagel 
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Equipment and manufacturers: 
Equipment Manufacturer 
ÄKTA purifier system Amersham Biosciences 
Beckman Avanti centrifuge J-25 Beckman 
Beckman centrifuge J2-MC Beckman 
Electroporation cuvettes (2 mm gap) Genetronics 
Gene Pulser electroporator BIO-RAD 
JA-10 Beckman rotor Beckman 
JA-14 Beckman rotor Beckman 
MR700 Microplate Reader Dynatech 
NanoDrop ND-1000 NanoDrop Technologies 
0.20 µm non-pyrogenic sterile filter Sarstedt 
PCR cycler PTC-200 MJ Research 
Quartz cuvettes, 1 cm Hellma 
RESOURCETM RPC column (3 ml) GE Healthcare 
SMART system Amersham Biosciences 
UV Shimadzu UV-160A spectrophotometer Shimadzu 
µRPC C2/C18 SC2.1/10 column Amersham Biosciences 
6.3 Recipes 
Agarose gel and gel electrophoresis buffer: 
AGAROSE GEL 
 
 
 
 
 
 
  1% Agarose gel: 
0.4 g agarose 
50 ml 1X TAE 
3 µl EtBr was applied after 
cooling the solution to less than 
60 °C 
 
50X  TAE buffer, 1 L:                                             
254 g Tris base                                                      
57.1 ml glacial acetic acid                                       
100 ml 0.1 M EDTA (pH 8) 
dH2O to a final volume of 1 L   
  
Autoclaved at 121 °C for 20 min                              
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Various media for different bacteria: 
MEDIA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
LB medium, 0.5 L: 
5 g NaCl 
5 g peptone 
2.5 g yeast extract 
 
Dissolved in dH2O to a final 
volume of 500 ml. Autoclaved 
at 121 °C for 20 min.    
MRS medium, 0.5 L: 
26 g MRS broth 
 
Dissolved in dH2O to a final 
volume of 500 ml. Autoclaved 
at 112 °C for 10 min.   
LB agar plates, 0.5 L: 
5 g NaCl 
5 g peptone 
2.5 g yeast extract 
10 g agar 
Dissolved in dH2O to a final 
volume of 500 ml. Autoclaved 
at 121 °C for 20 min. Addition 
of the appropriate antibiotic was 
applied after cooling the 
solution to less than 60 °C.  
MRS agar plates, 0.5 L: 
26 g MRS broth 
7.5 g agar 
 
Dissolved in dH2O to a final 
volume of 500 ml. Autoclaved 
at 112 °C for 10 min. Addition 
of the appropriate antibiotic was 
applied after cooling the 
solution to less than 60 °C.   
 
MRSSM medium, 0.1 L: 
5.2 g MRS broth 
17.1 g sucrose (0.5 M) 
2 g MgCl2 (0.1 M) 
 
Dissolved in dH2O to a final 
volume of 100 ml. Sterilized by 
filtrating through a 0.2 µm non-
pyrogenic sterile filter.   
GM17 medium: 
18.6 g M17 broth 
 
Dissolved in dH2O to a final 
volume of 500 ml. Autoclaved 
at 112 °C for 10 min. Addition 
of Tween 80 to a final 
concentration of 0.1 % (v/v) and 
glucose to a final concentration 
of 0.4 % (v/v).  
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Phosphate and elution buffers in cation-exchange chromatography: 
BUFFERS  
 
 
 
6.4 Primers 
6.4.1 PCR and Sequencing Primers 
PCR and sequencing primers: 
Primera) Primer Sequence 
SakPBb): 5’-acactttatgcttccggctcgtatgttgtgt-3’ 
PlnEAb): 5’-ccaaagttataaccgccccgattaaatccacctgtaattg 
   ctgttacttc-3’ 
PlnECb): 5’-ccatataaactaaaaaggctgagcttaacgaatacttttc 
   aaaataccacg-3’ 
PlnEFimmb): 5’-gcacagtaatcgatcgtaaagtatattagcatagc-3’ 
PlnEFimmstartb): 5’-cgttaagctcagcctttttagtttatatgg-3’ 
 
pLPV111sekFb,c): 5’-ccagctggcgaaagggggatgtgctgcaagg-3’ 
pLPV111sekRb,c): 5’-gcaattaatgtgagttagctcactcattagg-3’ 
T7d): 5’-taatacgactcactataggg-3’ 
SP6d): 5’-tatttaggtgacactatag-3’ 
 
a) All primers are produced by Eurogentec S.A. except the primers T7 and SP6 which are 
produced by Promega. 
b) The primer was put to use both in PCR and DNA sequencing. 
c) F = forward primer, R = reverse primer   
d) Sequencing primers used for verification of insert into the pGEM®-T Easy Vector. 
 
  
Phosphate buffer, 1 L: 
2.48 g NaH2PO4 
0.26 g Na2HPO4 
dH2O to 1 L 
Elution buffer, 1 L:  
2.48 g NaH2PO4 
0.26 g Na2HPO4 
58.44 g NaCl 
200 ml 2-propanol 
dH2O to 1 L 
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6.4.2 Mutagenic Primers 
Mutagenic primers and their primer sequences: 
Primera) Primer Sequenceb) 
G5xxxG9 Motif  
PlnE (G5A) F: 5’-ggatttaatcggggcgCttataactttgg-3’ 
PlnE (G5A) R:  3’-cctaaattagccccgcGaatattgaaacc-5’ 
PlnE (G5I) F: 5’-ggatttaatcggggcATttataactttgg-3’ 
PlnE (G5I) R: 3’-cctaaattagccccgTAaatattgaaacc-5’ 
PlnE (G5K) F: 5’-ggatttaatcggggcAAAtataactttgg-3’ 
PlnE (G5K) R: 3’-cctaaattagccccgTTTatattgaaacc-5’ 
PlnE (G5L) F: 5’-ggatttaatcggggcTTAtataactttgg-3’ 
PlnE (G5L) R: 3’-cctaaattagccccgAATatattgaaacc-5’ 
PlnE (G5Q) F: 5’-ggatttaatcggggcCAAtataactttgg-3’ 
PlnE (G5Q) R: 3’-cctaaattagccccgGTTatattgaaacc-5’ 
PlnE (G5S) F: 5’-ggatttaatcggggcAgttataactttgg-3’ 
PlnE (G5S) R: 3’-cctaaattagccccgTcaatattgaaacc-5’ 
PlnE (G9A) F: 5’-ggttataactttgCtaaaagtgttcgac-3’ 
PlnE (G9A) R: 3’-ccaatattgaaacGattttcacaagctg-5’ 
PlnE (G9I) F: 5’-ggttataactttATtaaaagtgttcgac-3’ 
PlnE (G9I) R: 3’-ccaatattgaaaTAattttcacaagctg-5’ 
PlnE (G9K) F: 5’-ggttataactttAAAaaaagtgttcgac-3’ 
PlnE (G9K) R: 3’-ccaatattgaaaTTTttttcacaagctg-5’ 
PlnE (G9L) F: 5’-ggttataactttTTAaaaagtgttcgac-3’ 
PlnE (G9L) R: 3’-ccaatattgaaaAATttttcacaagctg-5’ 
PlnE (G9Q) F: 5’-ggttataactttCAAaaaagtgttcgac-3’ 
PlnE (G9Q) R: 3’-ccaatattgaaaGTTttttcacaagctg-5’ 
PlnE (G9S) F: 5’-ggttataactttAgtaaaagtgttcgac-3’ 
PlnE (G9S) R: 3’-ccaatattgaaaTcattttcacaagctg-5’ 
G20xxxG24 Motif  
PlnE (G20A) F: 5’-gttgatgcaattgCttcagttgcaggcattcg-3’ 
PlnE (G20A) R: 3’-caactacgttaacGaagtcaacgtccgtaagc-5’ 
PlnE (G20I) F: 5’-gttgatgcaattATttcagttgcaggcattcg-3’ 
PlnE (G20I) R: 3’-caactacgttaaTAaagtcaacgtccgtaagc-5’ 
Appendix   
86 
 
PlnE (G20K) F: 5’-gttgatgcaattAAAtcagttgcaggcattcg-3’ 
PlnE (G20K) R: 3’-caactacgttaaTTTagtcaacgtccgtaagc-5’ 
PlnE (G20L) F: 5’-gttgatgcaattTTAtcagttgcaggcattcg-3’ 
PlnE (G20L) R: 3’-caactacgttaaAATagtcaacgtccgtaagc-5’ 
PlnE (G20Q) F: 5’-gttgatgcaattCAAtcagttgcaggcattcg-3’ 
PlnE (G20Q) R: 3’-caactacgttaaGTTagtcaacgtccgtaagc-5’ 
PlnE (G20S) F: 5’-gttgatgcaattAgttcagttgcaggcattcg-3’ 
PlnE (G20S) R: 3’-caactacgttaaTcaagtcaacgtccgtaagc-5’ 
PlnE (G24A) F: 5’-ggttcagttgcagCAattcgtggtattttg-3’ 
PlnE (G24A) R: 3’-ccaagtcaacgtcGTtaagcaccataaaac-5’ 
PlnE (G24I) F: 5’-ggttcagttgcaATTattcgtggtattttg-3’ 
PlnE (G24I) R: 3’-ccaagtcaacgtTAAtaagcaccataaaac-5’ 
PlnE (G24K) F: 5’-ggttcagttgcaAAAattcgtggtattttg-3’ 
PlnE (G24K) R: 3’-ccaagtcaacgtTTTtaagcaccataaaac-5’ 
PlnE (G24L) F: 5’-ggttcagttgcaTTAattcgtggtattttg-3’ 
PlnE (G24L) R: 3’-ccaagtcaacgtAATtaagcaccataaaac-5’ 
PlnE (G24Q) F: 5’-ggttcagttgcaCAAattcgtggtattttg-3’ 
PlnE (G24Q) R: 3’-ccaagtcaacgtGTTtaagcaccataaaac-5’ 
PlnE (G24S) F: 5’-ggttcagttgcaAgTattcgtggtattttg-3’ 
PlnE (G24S) R: 3’-ccaagtcaacgtTcAtaagcaccataaaac-5’ 
Tyrosine Residue  
PlnE (Y6F) F: 5’-atcggggcggttTtaactttggtaaaag-3’ 
PlnE (Y6F) R: 3’-tagccccgccaaAattgaaaccattttc-5’ 
PlnE (Y6L) F: 5’-atcggggcggttTAaactttggtaaaag-3’ 
PlnE (Y6L) R: 3’-tagccccgccaaATttgaaaccattttc-5’ 
PlnE (Y6R) F: 5’-atcggggcggtAGAaactttggtaaaag-3’ 
PlnE (Y6R) R: 3’-tagccccgccaTCTttgaaaccattttc-5’ 
PlnE (Y6W) F: 5’-atcggggcggttGGaactttggtaaaag-3’ 
PlnE (Y6W) R: 3’-tagccccgccaaCCttgaaaccattttc-5’ 
a) F = forward primer, R = reverse primer. All mutagenic primers are produced by Eurogentec 
S.A.  
b) Capital letters indicate the mutagenic positions. The three-letter codon of the new amino acid residue 
is marked in green.  
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6.5 Sizing Ladders 
      1 kb DNA Ladder:        100 bp Plus DNA Ladder:      100 bp DNA Ladder: 
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6.6 Plasmids 
 
A circle map of the pGEM®-T Easy Vector. The vector contains a marker for ampicillin-resistance 
(Ampr) and the gene lacZ. The gene encodes the β-galactosidase enzyme allowing for blue-white 
selection. The figure is adapted from Promega (96).  
 
 
 
A plasmid chart of pSAK20. The plasmid contains a marker for chloramphenicol-resistance (cat) as 
well as the operon orf4-sapKRTE, which is responsible for the transcriptional regulation, processing and 
secretion of sakacin A. orf4-sapKR constitute a three-component regulatory system (100).The gene orf4 
encodes a peptide pheromone, sapK encodes a histidine kinase, sapR encodes a response regulator, sapT 
encodes an ABC transporter and sapE encodes an accessory factor (99). 
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A plasmid chart of pLT100β. A pLPV111 derivative containing a marker for erythromycin-resistance 
(ermL), the gene encoding LcnG-β, one of the peptides constituting the two-peptide bacteriocin 
lactococcin G, and the gene encoding the lactococcin G immunity protein (LcnGimm). The gene 
encoding LcnG-β is fused to the sakacin P leader sequence and the sakacin A promoter (sapAp). The 
figure is adapted from Oppegård, C., 2005 (110).  
 
 
A plasmid chart of pPlnE100. A pLPV111 derivative constructed from pLT100β. The plasmid 
contains the sakacin A promoter (sapAp), the sakacin P leader sequence fused to the plnE-gene followed 
by the plnI-gene. The plasmid also contains a marker for erythromycin-resistance (ermL).  
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